

**UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF MASSACHUSETTS**

JOHN HANCOCK LIFE INSURANCE
COMPANY, JOHN HANCOCK VARIABLE
LIFE INSURANCE COMPANY, and
MANULIFE INSURANCE COMPANY (f/k/a
INVESTORS PARTNER INSURANCE
COMPANY),

Plaintiffs,

v.

ABBOTT LABORATORIES,

Defendants.

CIVIL ACTION NO. 05-11150-DPW
Hon. Judge Douglas P. Woodlock

**ABBOTT LABORATORIES' CORRECTED LIST OF WITNESSES, DEPOSITIONS
AND EXHIBITS**

Defendant Abbott Laboratories ("Abbott") respectfully submits this Corrected List of Witnesses, Depositions, and Exhibits pursuant to the Court's January 15, 2008 Second Amended Order Regulating Non-Jury Trial ("Order"). The original List of Witnesses, Depositions, and Exhibits filed by Abbott on February 18, 2008 inadvertently omitted pages at the end of Exhibit B due to a print format error in the Excel worksheet from which the list was printed. Abbott also has taken this opportunity to: (1) include on Exhibit B recently received additional information from John Hancock Life Insurance Company, John Hancock Variable Life Insurance Company, and Manulife Insurance Company (collectively, "Hancock") regarding its objection or lack of objection to certain exhibits; and (2) attach as Exhibit C a copy of a key to Hancock's objections that Abbott received from Hancock. This Corrected List of Witnesses, Depositions, and Exhibits contains no other corrections or changes.

A. Abbott Laboratories' List of Witnesses By Affidavit

Pursuant to Section II.4.a of the Court's Order, Abbott submits the following list of witnesses it intends to introduce by affidavit:

1. Stanley Bukofzer
2. Michelle Campbell
3. Jeanne Fox
4. Keith Hendricks
5. Jeffrey Leiden
6. John Leonard
7. Carol Meyer
8. Bruce Rodda
9. Ken Stiles
10. Avram Tucker

B. Witnesses to Be Presented by Deposition

Pursuant to Section II.4.b of the Court's Order, Abbott submits the following list of witnesses it intends to introduce through deposition testimony.

1. Stephen Blewitt
2. Marilyn Collicott
3. Deirdre Daeson
4. Diane D'Amico
5. Wilma Davis
6. Phil Deemer
7. Mark Hair
8. Scott Hartz

9. Jessica Hopfield
10. Lynn Klotz
11. Elizabeth Kowaluk
12. Andrea Landsberg
13. William Lee
14. Lise Loberg
15. Jim Looman
16. Tom Lyons
17. Christopher Martinez
18. John Mastromarino
19. Bruce McCarthy
20. Michael Meyer
21. Azmi Nabulsi
22. Roger Nastou
23. Perry Nisen
24. Christopher Silber
25. James Thomas
26. Tom Woidat

C. Abbott's Counter-Designations of Hancock's Deposition Designations

Abbott is also providing the Court with counter-designations of deposition testimony designated by Hancock:

1. Stanley Bukofzer
2. Michelle Campbell
3. Marilyn Collicott

4. Diane D'Amico
5. Phil Deemer
6. Jeanne Fox
7. Keith Hendricks
8. Jessica Hopfield
9. Andrea Landsberg
10. Jeffrey Leiden
11. John Leonard
12. Lise Loberg
13. Jim Looman
14. Tom Lyons
15. Bruce McCarthy
16. Carol Meyer
17. Michael David Meyer
18. Azmi Nabulsi
19. Bruce Rodda
20. James Thomas
21. Tom Woidat

D. Exhibits

Pursuant to Section II.4.c of the Court's Order, Abbott submits a list of exhibits to be introduced without objection as Exhibit A. Pursuant to Section II.4.d of the Court's Order, Abbott submits a list of exhibits to which Hancock has reserved the right to object, with the grounds of the objections Hancock has provided, as Exhibit B. Abbott also submits a copy of Hancock's key to its objections as Exhibit C.

ABBOTT LABORATORIES

By its attorneys

/s/ Eric J. Lorenzini

Eric J. Lorenzini

Michael S. D'Orsi
Peter E. Gelhaar (BBO #188310)
Michael S. D'Orsi (BBO #566960)
DONNELLY, CONROY & GELHAAR LLP
1 Beacon St., 33rd Floor
Boston, Massachusetts 02108
(617) 720-2880

and

Jeffrey I. Weinberger (Admitted Pro Hac Vice)
Gregory D. Phillips (Admitted Pro Hac Vice)
Eric J. Lorenzini (Admitted Pro Hac Vice)
Ozge Guzelsu (Admitted Pro Hac Vice)
MUNGER, TOLLES & OLSON LLP
355 South Grand Avenue, 35th Floor
Los Angeles, CA 90071
(213) 683-9100

Dated: February 19, 2008

CERTIFICATE OF SERVICE

I hereby certify that this document(s) filed through the ECF system will be sent electronically to the registered participants as identified on the Notice of Electronic Filing (NEF) and paper copies will be sent to those indicated as non registered participants on February 19, 2008.

Date: February 19, 2008.

/s/ Eric J. Lorenzini

4503507.1

John Hancock Life Insurance Company, et al. v Abbott Laboratories
Civil Action No. 05-11150-DPW

Abbott Laboratories' List of Agreed To Trial Exhibits

Trial Exhibit No.	Date	Production Range	Deposition Exhibit No.	Description
500	2/9/2000	ABBT0577899 - ABBT0577913		Operations Highlights 06/09/2000 Board Meeting Presentation
501	9/7/2001	ABBT0577959 - ABBT0577984		Operations Highlights 09/07/2001 Board Meeting Presentation
502	00/00/0000	JH000695 - JH000727	Klotz_0018	Klotz Memo re: Packet of materials (Klotz 18)
503	00/00/0000	ABBT372493 - ABBT372494	Leonard_0037	Abbott Laboratories Project Overview ABT-518 Closed (Leonard 37)
504	2/28/2001	ABBT0556317 - ABBT0556317	Andrews_0005	ABT-594 Questions for Paul Andrews (Andrews 5)
505	00/00/0000	AND00033 - AND00092	Andrews_0006	Presentation titled "Pathways and Pharmacology of Emesis" (Andrews 6)
506	00/00/0000	ABBT0051885 - ABBT0051888	Thomas_0003	Report titled "80 Percent Power Curve for Varying Effect Size for Neuropathic Pain Based on M98833 and Gabapentin Results" (Thomas 3)
507	00/00/0000	JHII021645 - JHII021646	Martinez_0011	Document Index Report (Martinez 11)
508	00/00/2000	ABBT0047907 - ABBT0047908		ABT-594 Probability Assessment Worksheet (McCarthy 119)
509	7/4/2000	JH000654 - JH000658		Abbott Ketolide Antibiotic ABT-773
510	00/00/0000		Gold_0001	Summary of Anticipated Expert Testimony of Dr. Barry Gold (Gold 1)
511	00/00/0000	JH002180 - JH002201	Klotz_0026	Pertinent Information on Interview Candidates (Klotz 26)
512	00/00/0000	JH001103 - JH001104		File Memo re: Abbott Laboratories Non Recourse
513	00/00/0000	JHII021956 - JHII021958		Abbott Laboratories BA Asset Portfolio Details
514	5/13/1997	JHII012335 - JHII012354	Blewitt_0001	Purchase Recommendation re: Metabolex Inc. (Blewitt 1)
515	6/5/1998	JHII012446 - JHII012446	Blewitt_0002	Report of Purchase re: Alza Corp. (Blewitt 2)
516	6/10/1998	JHII012404 - JHII012411		Purchase Recommendation re: Purdue Pharma etal. (Blewitt 3)
517	8/29/1998	JH001702 - JH001706	Klotz_0003	Klotz Letter re: Modified Proposal, Consulting Contract and Product Development Tool (Klotz 3)
518	9/9/1998	JH001694 - JH001698	Klotz_0004	Klotz Letter re: Modification to the Consulting Agreement (Klotz 4)
519	1/13/1999	JHII012240 - JHII012250	Blewitt_0004	Purchase Recommendation re: Celgene Corp. (Blewitt 4)
520	5/6/1999	JH001699 - JH001701	Klotz_0005	Klotz Letter re: Draft of General Consulting Agreement (Klotz 5)
521	06/00/1999	ABBT0018986 - ABBT0019095		ABT-594 Development Plan June 1999

John Hancock Life Insurance Company, et al. v Abbott Laboratories
Civil Action No. 05-11150-DPW

Abbott Laboratories' List of Agreed To Trial Exhibits

Trial Exhibit No.	Date	Production Range	Deposition Exhibit No.	Description
522	6/4/1999	JHII012420 - JHII012428	Blewitt_0006	Purchase Recommendation re: Purdue (Blewitt 6)
523	6/25/1999	JHII012277 - JHII012283	Blewitt_0007	Purchase Recommendation re: Elan (Blewitt 7)
524	7/1/1999	JHII012251 - JHII012262	Blewitt_0008	Additional Purchase Recommendation re: Celgene Corp. (Blewitt 8)
525	8/20/1999	JHII012449 - JHII012461	Blewitt_0009	Report of Purchase re: Lilly Del Mar (Blewitt 9)
526	12/21/1999	ABBT0051889 - ABBT0051889		Thomas Email re: 114 Sample Size
527	00/00/2000		Hartz_0018	Excel spreadsheet of Annual Sales (Hartz 18)
528	00/00/2000		Nastou_0004	Financial Chart re: Annual Sales (Nastou 4, Walsh 7)
529	00/00/2000	ABBT338037 - ABBT366059	Woidat_0010	Cholinergic Channel Modulator (ABT-594) 2000 AGU Development Cost Summary (Woidat 10)
530	00/00/2000	JHII021620 - JHII021626		John Hancock Abbott Compound Summary Cholinergic Channel Modulator (ABT-594) 2000
531	00/00/2000	JH002212 - JH002226		Macrolide Resistance and Erythromycin Resistance Determinants among Belgian Streptococcus Pyogenes and Streptococcus Pneumoniae Isolates
532	00/00/2000	ABBT0003362 - ABBT0003370; ABBT0003416 - ABBT0003418; ABBT329442 - ABBT329558; ABBT299286-ABBT299297; ABBT299147-ABBT299158		ABT-518 Total-Base Project Information (Hopfield 21)
533	1/28/2000	JH002312 - JH002313		Proposed Summary of Terms 01/28/2000
534	2/8/2000	ABBT0065818 - ABBT0065896	Thomas_0005	Executed Protocol M99-114 02/08/2000 (Thomas 5)
535	2/29/2000	ABBT0065897 - ABBT0065981	McCarthy_0069	Clinical Protocol ABT-594 M99-114 Amendment One 02/29/2000
536	3/7/2000	JH002308 - JH002309		Proposed Summary of Terms 03/07/2000
537	3/9/2000	ABBT0141929 - ABBT0141983		Matrix Metalloproteinase Inhibitors Project
538	04/00/2000	ABBT0107546 - ABBT0107551		ABT-594 Descriptive Memorandum April 2000
539	4/5/2000	ABBT246414 - ABBT246415		Weiland Email re: Hancock R&D Funding
540	5/2/2000	AL000135 - AL000135		Blewitt Email re: Update [Transaction]

John Hancock Life Insurance Company, et al. v Abbott Laboratories
Civil Action No. 05-11150-DPW

Abbott Laboratories' List of Agreed To Trial Exhibits

Trial Exhibit No.	Date	Production Range	Deposition Exhibit No.	Description
541	5/8/2000	JH002423 - JH002429		Blewitt Memo re: Proposed John Hancock Abbott Laboratories Transaction
542	5/16/2000	ABBT364740 - ABBT364740		Silber Email re: Monthly Highlights for the Analgesia Venture
543	5/26/2000	ABBT0008178 - ABBT0008181		Cohen Email Forwarding Latest Proposed Terms Sheet
544	5/31/2000	ABBT246447 - ABBT246454		Matrix Metalloproteinase Inhibitors Program Descriptive Memorandum May 2000
545	06/00/2000	ABBT0570747 - ABBT0570770	Klotz_0002	ABT-773 Ketolide Antibiotic 2000 Strategic Marketing Plan June 2000
546	6/2/2000	JH003089 - JH003100		Klotz Email re: My CV and Thoughts About Strategy (Klotz 2)
547	6/5/2000	ABBT246466 - ABBT246471		ABT-773 Descriptive Memorandum May 2000
548	6/7/2000	AL000198 - AL000199	Deemer_0005	Deemer Email re: John Hancock Abbott Funding Collaboration (Deemer 5)
549	6/8/2000	JHII012376 - JHII012388		Purchase Recommendation re: Pharma Marketing Ltd
550	6/20/2000	JH003080 - JH002090	Klotz_0007	Klotz Email Preliminary Abbott Basket Analysis (Klotz 7)
551	6/27/2000	JH003058 - JH003069	Klotz_0008	Klotz Email re: Materials for your Comments (Klotz 8)
552	6/27/2000	AL000115 - AL000119		Proposed Summary of Terms 06/27/2000
553	7/3/2000	JH003032 - JH003057		Klotz Email re: Update on Cytostatic Area
554	7/4/2000	JH003027 - JH003031	Klotz_0022	Klotz Email re: Ketolide Research Summary (Klotz 22)
555	7/7/2000	ABBT0082516 - ABBT0082516		McCarthy Email re: M99-114 Protocol Change Discussion
556	7/11/2000	JH003014 - JH003026	Klotz_0011	Klotz Email re: Rest of Research Summaries (Klotz 11)
557	7/11/2000	JH003007 - JH003013		Klotz Email re: Edit of Neuropathic Pain Summary
558	7/14/2000	JH000675 - JH000678	Klotz_0010	Klotz Email re: Update on Interviews (Klotz 10)
559	7/18/2000	JH002999 - JH003001	Klotz_0012	Klotz Email re: First Neuropathic Pain Interview (Klotz 12)
560	7/21/2000	JH002993 - JH002997	Blewitt_0029	Klotz Email to Blewitt re: Moellering Interview (Blewitt 39)
561	7/23/2000	JH002984 - JH002988	Klotz_0013	Klotz Email re: Questions for Abbott (Klotz 13)

John Hancock Life Insurance Company, et al. v Abbott Laboratories
Civil Action No. 05-11150-DPW

Abbott Laboratories' List of Agreed To Trial Exhibits

Trial Exhibit No.	Date	Production Range	Deposition Exhibit No.	Description
562	7/28/2000	JH002973 - JH002979		Klotz Email re: Abbott interview write-up
563	08/00/2000	ABBT256634 - ABBT356645		ABT-518 Transition Strategy MMPI August 2000
564	8/4/2000	AL000099 - AL000102	Deemer_0023	Deemer Email re: Request for Hancock Slide (Deemer 23)
565	8/17/2000	AL000138-AL000175		Deemer Email re: Draft Agreement
566	8/29/2000	ABBT0080232 - ABBT0080233		Thomas Email re: M99-114 graph data
567	9/18/2000	JH003342 - JH003346	Lee_0004	Lee Email re: Abbott Hancock - Memo re: Research Funding Agreement (Lee 4)
568	9/18/2000	JHII021647 - JHII021649		GBSA Spreads to On the run Treasuries 9/16 -9/25/2000
569	9/21/2000	JH001185 - JH001202		Purchase Recommendation re: Abbott Labs ("Non-Recourse")
570	9/21/2000	JH005573 - JH005573		Bond Investment Committee Meeting Minutes 09/21/2000
571	9/21/2000	JH001203 - JH001220		Purchase Recommendation re: Abbott Labs ("Non-Recourse")
572	9/28/2000	ABBT233741 - ABBT233749	McCarthy_0019; Silber_0021	Clinical Trial Recruitment and Centralized Screening Program for Painful Diabetic Neuropathy (Silber 21, McCarthy 19)
573	9/28/2000	ABBT0051892 - ABBT0051904	Thomas_0014	Thomas Email re: ABT-594 M99-114 Slides for David (Thomas 14)
574	9/29/2000	ABBT0105598 - ABBT0105598		Silber Email re: 594 Neuropathic pain study
575	10/3/2000	ABBT0107081 - ABBT0107081		McCarthy Email re: ABT 594/963 Purdue meeting
576	10/10/2000	JH005551 - JH005553		Meeting Minutes from John Hancock Committee of Finance Records for 10/10/2000
577	10/27/2000	JH000778 - JH000778		Deemer Email re: ABT-980 [Forwarding Letter to the Clinical Community Regarding 980]
578	11/00/2000	ABBT144600.ur - ABBT144609.ur		ABT-594 Descriptive Memorandum November 2000
579	11/1/2000	ABBT245829 - ABBT245835		ABT-518 Descriptive Memorandum February 2001
580	11/20/2000	ABBT0558681 - ABBT0558683	Leonard_0051	Fox Email re: FDA Telephone Contact Report ABT-773 (Leonard 51)
581	11/21/2000	JH004980 - JH004988		Pals Email re: Exhibit for Development Plans
582	11/27/2000	ABBT205257 - ABBT205259	Fox_0005	FDA Contact Report [ABT-773 End of Phase 2 Meeting] (Fox 5)

John Hancock Life Insurance Company, et al. v Abbott Laboratories
Civil Action No. 05-11150-DPW

Abbott Laboratories' List of Agreed To Trial Exhibits

Trial Exhibit No.	Date	Production Range	Deposition Exhibit No.	Description
583	12/00/2000	ABBT0017554 - ABBT0017554	McCarthy_0028	December 2000 "Top" Issues (McCarthy 28)
584	12/14/2000	ABBT233539 - ABBT233540	McCarthy_0029	Collicott Email re: Clinical Study (McCarthy 29)
585	12/21/2000	ABBT0118174 - ABBT0118203	McCarthy_0093	McCarthy Email re: Purdue Presentation (McCarthy 93)
586	00/00/2001	ABBT0063643 - ABBT0063649		ASCO 2001 MMPI Update
587	01/00/2001	ABBT0000302 - ABBT0000308		ABT-773 Project Status Report Monthly Highlights January 2001
588	01/00/2001	ABBT0000322 - ABBT0000327	Collicott_0027; Leonard_0019	ABT-594 Project Status Report Monthly Highlights January 2001 (Leonard 19, Collicott 27)
589				
590	1/25/2001	ABBT301935 - ABBT301941		Kowaluk Email re: Summary of Success Probabilities
591	1/25/2001	ABBT0012433 - ABBT000012496		Dart Email re: APU Prioritization Meeting
592	1/25/2001	ABBT0102282 - ABBT246130	Silber_0043	Silber Email to Sullivan re: ABT-594 (Silber 43)
593	1/31/2001	ABBT0014658 - ABBT0014665		ABT-518 Protocol Number M00235 Incorporating Amendment Nos. 1 and 2 January 2001
594	02/00/2001	JH008153 - JH008158		ABT-773 Descriptive Memorandum February 2001
595	02/00/2001	JH008159 - JH008164		ABT-627 Descriptive Memorandum February 2001
596	02/00/2001	JH008165 - JH008173		ABT-594 Descriptive Memorandum February 2001
597	02/00/2001	JH008174 - JH008178		ABT-751 Descriptive Memorandum February 2001
598	02/00/2001	JH008179 - JH008185		ABT-492 Descriptive Memorandum February 2001
599	02/00/2001	JH008186 - JH008192		ABT-510 Descriptive Memorandum February 2001
600	02/00/2001	JH008193 - JH008199		ABT-518 Descriptive Memorandum February 2001
601	02/00/2001	JH008200 - JH008205		Farnesyltransferase Inhibitor Descriptive Memorandum February 2001
602	02/00/2001	JH008206 - JH008209		Dopamine Receptor Agonist Program Descriptive Memorandum February 2001
603	02/00/2001	ABBT0000412 - ABBT0000417		ABT-594 Neuronal Nicotinic Receptor Agent February 2001
604	02/00/2001	ABBT0000387 - ABBT0000399		ABT-773 Tab Ketolide Antibiotic Tablet February 2001

John Hancock Life Insurance Company, et al. v Abbott Laboratories
Civil Action No. 05-11150-DPW

Abbott Laboratories' List of Agreed To Trial Exhibits

Trial Exhibit No.	Date	Production Range	Deposition Exhibit No.	Description
605	2/6/2001	ABBT0012431 - ABBT0012432		Summary of Success Probabilities by Project and Franchise Portfolio Analysis January 2001
606	2/12/2001	ABBT205042 - ABBT205046	Bukofzer_0007	ABT-773 Update February 12, 2001 (Bukofzer 7)
607	2/12/2001	ABBT0576828 - ABBT0576871	Meyer_0010	Presentation re: ABT-773 Update February 12, 2001 (Meyer 10)
608	2/22/2001	ABBT204959 - ABBT205279		Sun Email re: 773 Material
609	2/27/2001	ABBT0114639 - ABBT0114639		Verlinden Email re: ABT-594 partnering
610	2/28/2001	ABBT0003465 - ABBT0003465		Leonard Memo re: Monthly Highlights Feb 2001
611	03/00/2001	ABBT287552 - ABBT287557		Summary of Success Probabilities by Project and Franchise Portfolio Analysis March 2001
612	03/00/2001	ABBT0000349 - ABBT0000354		ABT-518 Matrix Metalloproteinase Inhibitor Monthly Status Project Report March 2001
613	03/00/2001	ABBT0000429 - ABBT0000438		ABT-773 Ketolide Antibiotic Tablet Monthly Status Project Report March 2001
614	03/00/2001	ABBT271783 - ABBT271816		ABT-773 Agenda Presentation
615	3/1/2001	ABBT0164029 - ABBT0164036		Frapaise Email re: Memo to Participants of the Dev. Portfolio Mtg-March 7-9
616	3/2/2001	ABBT0037509 - ABBT0037608		Russell Memo re: 2001 Plan Final Reference Package
617	3/6/2001	ABBT0119894 - ABBT0119895		Silber Email re: ABT-594 - Purdue Response
618	3/8/2001	ABBT0060705 - ABBT0060706		MMPI Working Group Meeting Minutes 03/08/2001
619	3/9/2001	ABBT297558 - ABBT297583		ABT-594 Presentation re: Abbott Portfolio Review March 7-9, 2001
620	3/9/2001	ABBT0048632 - ABBT00048645		ABT-594 Presentation re: Abbott Portfolio Review March 7-9, 2001
621	3/9/2001	ABBT0092919 - ABBT0092921		Agenda for Portfolio Review Meeting March 7-9, 2001
622	3/9/2001	ABBT0013203 - ABBT0013214		ABT-773 Craft Presentation re: Abbott Portfolio Review March 7-9, 2001
623	3/12/2001	ABBT0059464 - ABBT0059464		D'Amico Email re: M00235 Patient
624	3/12/2001	JH010033 - JH010142	Lee_0018	Adams Email re: Latest Version (Lee 18)
625	3/13/2001	JH01021612 - JH01021619		Compound Summary for Cholinergic Channel Modulator ABT-594
626	3/13/2001	JH001103 - JH001104	Blewitt_0031	File Memo re: Abbott Laboratories "Non Recourse" (Blewitt 31)

John Hancock Life Insurance Company, et al. v Abbott Laboratories
Civil Action No. 05-11150-DPW

Abbott Laboratories' List of Agreed To Trial Exhibits

Trial Exhibit No.	Date	Production Range	Deposition Exhibit No.	Description
627	3/13/2001	JHII021607 - JHII021611		Compound Summary for Matrix Metalloproteinase Inhibitor MMPI Program ABT-518
628	3/13/2001	JHII021612 - JHII021619	Hair_0022	Compound Summary for Cholinergic Channel Modulator ABT-594 (Hair 22)
629	3/14/2001	ABBT0060789 - ABBT0060789		Rieser Email re: M00235 PK Validation
630	3/16/2001	ABBT0509109 - ABBT0509109		Nabulsi/Janus Letter re: M00235 Study
631	3/19/2001	ABBT120465.UR - ABBT120513.UR		ABT-773 Update March 19, 2001 Presentation
632	3/21/2001	ABBT364018 - ABBT364020		Woidat Email re: Proposed APU Target Adjustments
633	3/22/2001	ABBT300130 - ABBT300132		Gjelsten Email re: MMPI Working Group Meeting Minutes: 3/8/01
634	04/00/2001	ABBT0000355 - ABBT0000360		ABT-518 Matrix Metalloproteinase Inhibitor Monthly Status Project Report April 2001
635	04/00/2001	ABBT0000491 - ABBT0000496		ABT-594 Neuronal Nicotinic Receptor Agent Monthly Status Project Report April 2001
636	4/12/2001	ABBT0026337 - ABBT0026338	Deemer_0040	MMPI Working Group Meeting Minutes 04/12/2001
637	4/23/2001	ABBT0001749 - ABBT0001758		M99114 Study Review 04/23/2001 Presentation
638	05/00/2001	ABBT0000508 - ABBT0000519		ABT-773 Ketolide Antibiotic Tablet Monthly Status Project Report May 2001
639	5/2/2001	ABBT0001769 - ABBT0001839		ABT-594 Phase 2B Diabetic Neuropathic Pain Results M99114 Study Review 05/02/2001 Presentation
640	5/4/2001	ABBT335154 - ABBT335154		M. Meyer Email re: ABT-594 Memo
641	5/7/2001	ABBT361448 - ABBT361455		Woidat Email re: Leiden "Woidat" Questions - Responses
642	5/20/2001	ABBT0037615 - ABBT0037616		Global Pharmaceutical Research & Development-2001 April Update- Leiden Follow-up Package
643	5/22/2001	ABBT0064226 - ABBT0064233		Nisen Email to Leonard re: ABT-518
644	5/28/2001	ABBT0033486 - ABBT0033494		Bronson Email re: ABT-518 Slides
645	6/7/2001	ABBT0045226 - ABBT0045227		MMPI Monthly Meeting Agenda with handwritten notes
646	6/7/2001	ABBT0026340 - ABBT0026342		MMPI Working Group Minutes 6/7/01 (Leonard 34)
647	6/11/2001	ABBT0063625 - ABBT0063626		Nisen Email re: MMPI Data from Subject X Additional Info
648	6/17/2001	ABBT224941 - ABBT224983		Moore Email re: Final Copy of 773 Decision Analysis

John Hancock Life Insurance Company, et al. v Abbott Laboratories
Civil Action No. 05-11150-DPW

Abbott Laboratories' List of Agreed To Trial Exhibits

Trial Exhibit No.	Date	Production Range	Deposition Exhibit No.	Description
649	6/20/2001	ABBT229367 - ABBT229448	Bukofzer_0014	C. Meyer Email re: ABT 773 Taiso/Abbott Meeting June 26 (Bukofzer 14)
650	6/20/2001	MCK00014 - MCK00108		McKinsey Portfolio Analysis of 2001 Abbott Global Pharmaceutical Development Assets
651	6/21/2001	ABBT0507879 - ABBT0507879		Nabulsi Letter re: ABT-518
652	6/28/2001	JHII021462 - JHII021462		GBSA Spreads to On the run Treasuries
653	07/00/2001	ABBT0000612 - ABBT0000618		ABT-594 Neuronal Nicotinic Receptor Agent Monthly Status Project Report July 2001
654	07/00/2001	ABBT0000589 - ABBT0000598		ABT-773 Ketolide Antibiotic Tablet Monthly Status Project Report July 2001
655	7/23/2001	ST-AUDIT18511 - ST-AUDIT18594		ABT-773 Dosing Options 07/25/2001 Presentation
656	7/30/2001	ABBT245647 - ABBT245647		Deemer Email to Norbeck re: MMPI
657	7/30/2001	ABBT317214 - ABBT317214		Kowaluk Email re: ABT-594 DSG Analysis Preview Meetings
658	8/10/2001	ABBT0049970 - ABBT0049977		Davidson Memo re: ABT-518
659	8/14/2001	ABBT0049980 - ABBT0049981		Nisen Memo re: ABT-518
660	8/21/2001	ABBT0001974 - ABBT0002029	Klaus_00034	M99-114 Study Review Back-up
661	8/21/2001	ABBT311519 - ABBT311637	Meyer_0023; McCarthy_0054	ABT-594 GPEC Review August 21, 2001
662	9/13/2001	ABBT127868.ur - ABBT127868.ur	McCarthy_0055	Probability Assessment Worksheet 09/13/2001 (McCarthy 55)
663	9/17/2001	ABBT245619 - ABBT245619		Deemer Email re: ABT-518 [Handling Out Licensing of ABT-518]
664	9/20/2001	JH008372 - JH008372		Pals Letter re: Research Funding Agreement Dated as of 03/13/2001 Termination of MMPI Program and ABT-518
665	9/27/2001	ABBT113285.ur - ABBT113315.ur	McCarthy_0063	ABT-594 PEC Review Book Proposal for Additional Study and Background (Nonstandard Format)
666	9/28/2001	ABBT245788 - ABBT245805	Deemer_0027	Carlson Email re: Template for Outlicensing Update (Deemer 27)
667	10/00/2001	ST-AUDIT13231 - ST-AUDIT13235		Center for Clinical Assessment Project Status Report October 2001
668	11/16/2001	ABBT0033833 - ABBT0033833		Pals Letter re: Research Funding Agreement Dated as of 03/13/2001 Termination of ABT-594
669	11/20/2001	ABBT0025973 - ABBT0025973		Pals Letter re: Research Funding Agreement Dated as of 03/13/2001 Termination of ABT-594

John Hancock Life Insurance Company, et al. v Abbott Laboratories
Civil Action No. 05-11150-DPW

Abbott Laboratories' List of Agreed To Trial Exhibits

Trial Exhibit No.	Date	Production Range	Deposition Exhibit No.	Description
670	11/26/2001	JH000787 - JH000802	Hendrick_0009	Pals Letter re: Research Funding Agreement Dated as of 03/13/01 - 2002 Preliminary Annual Research Plan (Hendricks 9)
671	12/18/2001	JH001065 - JH001068	Blewitt_0044	Lyons Letter re: Research Funding Agreement Dated as of 03/13/01 2001 Program Status Report and Related Cost Summary - (Blewitt 44)
672	12/31/2001	JHII021496 - JHII021498		Journal Entries and Balance Sheet
673	1/7/2002	ABBT207773 - ABBT207775		Sun Memo re: PEC and ABT-773 Status
674	9/30/2002	JH003142 - JH003158		Blewitt Email re: Abbott Labs
675	11/7/2002	ABBT0518029 - ABBT0518031		Tyree Memo re: October 2002 Highlights
676	12/00/2002	ABBT220660 - ABBT220672		January 2002 ABT-773 Presentation for Miles White
677	00/00/2003	JHII021620 - JHII021626	Hair_0023	Compound Summary Cholinergic Channel Modulator ABT-594 (Hair 23)
678	00/00/2003	JHII021627 - JHII021635		Compound Summary Dopamine Receptor Agonist Program ABT-724
679	1/16/2003	ABBT0016048 - ABBT0016051		Johansson Letter re: Research Funding Agreement Dated as of 03/31/01
680	1/22/2003	JH001105 - JH001105		Certificate Pursuant to Bond Investment Committee Guidelines Adopted 03/19/99
681	1/30/2003	JH001111 - JH001168		Johansson Letter re: Elitra Pharmaceuticals
682	3/14/2003	JH002447 - JH002447		Welch Email re: FW: Abbott Labs Heads Up
683	4/13/2003	JH003122 - JH003136	Nastou_0012	Blewitt Email re: Abbott (Nastou 12)
684	06/00/2003	JHII021645 - JHII021646		List of Reviewers with Corresponding Pallet Number
685	6/11/2003	JH003113 - JH003115		Blewitt Email re: Abbott Research and Development Agreement
686	9/22/2003	JH001071 - JH001091		Lyons Letter re: Final 2003 Development Plans
687	11/12/2003	JH001283 - JH001290		Tyree Letter re: Annual Research Plan for 2004 and 2005
688	12/19/2003	JHII012075 - JHII012078		Background of the Investment in Research Funding Agreement
689	12/23/2003	JH002323 - JH002339		Blewitt Email re: Abbott
690	00/00/2004		Walsh_0007	Drug Probability Peak Sales Launch Sales Model (Walsh 1)
691	3/19/2004	JHII012071 - JHII012074		Investment Review Report re: Execution Version of Agreement
692	4/12/2004	JHII011883 - JHII011886	Hair_0001	Blewitt Letter re: Research Funding Agreement Dated 03/13/01 (Hair 1)

John Hancock Life Insurance Company, et al. v Abbott Laboratories
Civil Action No. 05-11150-DPW

Abbott Laboratories' List of Agreed To Trial Exhibits

Trial Exhibit No.	Date	Production Range	Deposition Exhibit No.	Description
693	6/23/2004	ABBT0000114 - ABBT0000114		Desideri Letter re: Research Funding Agreement Dated 03/13/01
694	7/19/2004	ABBT0000265 - ABBT0000266		Campbell Email re: Hancock Audit
695	8/6/2004	ABBT0126614 - ABBT0126615		Wendrickx Email re: Invoices
696	8/31/2004	ABBT0000257 - ABBT0000260		Campbell Email re: FW: John Hancock Audit
697	8/31/2004	ABBT0126635 - ABBT0126639		Martinez Email re: FW: John Hancock Audit
698	9/13/2004	JHII012067 - JHII012070		Draft of Investment Review Report re: Execution Version of Agreement
699	9/28/2004	ABBT0000255 - ABBT0000256; ABBT0126645 - ABBT0126647	Campbell_0025	Campbell Email re: Status of Documents Available for Review re: John Hancock Audit (Campbell 25)
700	10/26/2004	ABBT0000250 - ABBT0000253		Campbell Email re: FW: Status on Documents Available for Review
701	11/5/2004	ABBT0000137 - ABBT0000138		D'Amore Letter re: Research Funding Agreement Dated 03/14/01
702	11/16/2004	ABBT0027246 - ABBT0027263		Tyree Letter re: Research Funding Agreement Dated 03/13/01
703	12/13/2004	ABBT0027991 - ABBT0028015		License Agreement between Abbott and ALS
704	12/13/2004	JHII012062 - JHII012066		Draft of Investment Review Report re: Execution Version of Agreement
705	1/4/2005	JH0II11167 - JH0II11168		Daesen Email re: Abbott
706	1/18/2005	ABBT0000235 - ABBT0000235		Martinez Email re: Audit - Thursday
707	1/31/2005	ABBT0126905 - ABBT0126908		Wendrickx Email re: Hancock Audit
708	2/24/2005	JHII011221 - JHII011221		Hartz Email re: Abbott
709	3/9/2005	JHII021636 - JHII021636		John Hancock Abbott Research Funding Agreement Audit MH Notes 03/09/05
710	3/11/2005	JHII021637 - JHII021637		John Hancock/Abbott Summary of Available Monthly Project Status Reports as of 03/11/05
711	3/15/2005	ABBT0000280 - ABBT0000284		Campbell Email re: FW: JH Abbott Audit Documentation
712	3/16/2005	JHII021644 - JHII021644		Summary of Available Monthly Project Status Reports as of 03/16/05
713	3/17/2005	JHII021526 - JHII021594		John Hancock Document Index
714	3/18/2005	JHII021638 - JHII021643		John Hancock/Abbott Summary of Available Monthly Highlights Interoffice Memos Documents Received as of 03/18/05
715	3/22/2005	ABBT0126575 - ABBT0126575		Campbell Email re: Hancock Audit
716	3/25/2005	ABBT0000270 - ABBT0000271		Campbell Email re: John Hancock Audit

John Hancock Life Insurance Company, et al. v Abbott Laboratories
Civil Action No. 05-11150-DPW

Abbott Laboratories' List of Agreed To Trial Exhibits

Trial Exhibit No.	Date	Production Range	Deposition Exhibit No.	Description
717	3/27/2005	ABBT0005098 - ABBT0005112; 2606980; 2602418	Campbell_0006	Invoice No. 2606980 from Special Counsel for \$123.50 (Campbell 6)
718	3/28/2005	JHII021598 - JHII021598		Documents that were Received by Stone Turn but not Identifiable or Previously Included in the Document Index
719	6/13/2005	JHII012079 - JHII012083		Investment Review Report re: Execution Version of Agreement
720	9/15/2005	ABBT372504 - ABBT372504		Hoff-Smith Email re: Update on ABT-518
721	1/20/2006	ABBT0026105 - ABBT0026116		Lebold Letter re: Research Funding Agreement Dated 03/13/01
722	2/6/2006		Martinez_0007	Hancock's Responses and Objections to Abbott's 1st Set of Interrogatories (Martinez 7)
723	00/00/0000			Electronic version of Monte Carlo Simulation (Excel spreadsheet) produced by John Hancock
724	00/00/0000			Electronic version of StoneTurn Index (Excel spreadsheet) titled John Hancock-Document Index
725	00/00/0000	ST-AUDIT00001 - ST-AUDIT42765		All documents with prefix ST-AUDIT
726	00/00/2001	MCK00537-539	Hopfield_0014	McKinsey Project Map - 2001
727	3/16/2001	ABBT0033105		Nabulsi and Janus Letter re: M00-235
728	3/16/2001	ABBT0033117		Nabulsi and Janus Letter re: M00-235
729	3/16/2001	ABBT0033118		Nabulsi and Janus Letter re: M00-235
730	5/12/2001			ASCO News Release titled, "Nearly 25,000 Cancer Specialists Meet in San Francisco for ASCO Annual Meeting"
731	1/19/2007		Fairweather_0001	Expert Report of Dr. William R. Fairweather
732	6/25/2007			Advanced Life Sciences Form 8-K for the period of June 21, 2007
733	12/3/2007			Revised Expert Report of Alan Friedman
734	12/3/2007			Revised Expert Report of Dr. Barry I. Gold
735	02/00/2001	ABBT0000343-ABBT0000348	Damico_0003	ABT518 Matrix Metalloproteinase Inhibitor
736	1/28/2005			D'Amore Letter re: Research Funding Agreement Dated 03/14/01
737	4/21/2005			D'Amore Letter re: Research Funding Agreement Dated 03/13/01
738	9/16/2005			District Court's Memorandum and Order granting Hancock's Motion For Summary Judgment

John Hancock Life Insurance Company, et al. v Abbott Laboratories
Civil Action No. 05-11150-DPW

Abbott Laboratories' List of Agreed To Trial Exhibits

Trial Exhibit No.	Date	Production Range	Deposition Exhibit No.	Description
739	2/6/2006		Martinez_0007	Hancock's Responses and Objections to Abbott's 1st Set of Interrogatories
740	5/10/2006			Hancock's Supplemental Responses To Abbott's Interrogatories Nos. 5(c), 5(d), 6(c), 6(d), and 10
741	6/23/2006			Hancock's Responses and Objections to Abbott's 2nd Set of Interrogatories
742	9/28/2006			First Circuit Court of Appeal's decision affirming the District Court's Order
743	4/30/2007			Hancock's Responses and Objections to Abbott's 3rd Set of Interrogatories
744	6/28/2007			Troake Email confirming that Abbott will produce the set of documents that StoneTurn received in the audit
745	7/3/2007			Dion Letter producing the ST-AUDIT documents
746	7/16/2007			Hancock's Supplemental Responses to Abbott Interrogatory Nos 2, 3, 5(A)(B)(F), 6(A)(B)(F), and 7
747	11/8/2007			Second Amended Complaint (Docket # 198)
748	2/2/2001	ABBT0002314 - ABBT0002489	Leonard_0036; Collicot_0032	Project Review ABT-089 and ABT-594
749	12/21/2000	ABBT112987.ur - ABBT112992.ur		Assumption Memos - Monthly Highlights
750	01/00/2001	ABBT0012369 - ABBT0012387		Portfolio Analysis January 2001 Review Reference Materials
751	04/00/2001	ABBT0032090 - ABBT0032144		Portfolio Analysis April 2001 Review PPD and Knoll Assets Reference Materials
752	3/7/2001	ABBT232209 - ABBT232232		Abbott Portfolio Review March 7-9, 2001
753	3/7/2001	ABBT0116656 - ABBT0116659		Portfolio Review Meeting Documents
754	5/4/2001	ABBT0048541 - ABBT0048584		Pain Therapeutic Area - Global Pharmaceutical R & D strategy retreat May 2-4, 2001
755	5/4/2001	ABBT0060730 - ABBT0060767		Abbott Oncology - Global Pharmaceutical R & D Strategy Retreat May 2-4, 2001
756	11/9/2001	ABBT0003478 - ABBT0003481		Interoffice Memorandum re: Monthly Highlights October 2001
757	2/5/2001	ABBT0108214 - ABBT0108370		February 2001 Leiden ABT-594 Presentation
758	3/9/2001	ABBT004510 - ABBT0004511		Deemer Email re: MMPI Program Update
759	1/26/2001	ABBT144630.ur - ABBT144646.ur	Leonard_0021	Analgesia Venture 2001 Plan Revised 1/26/01

John Hancock Life Insurance Company, et al. v Abbott Laboratories
Civil Action No. 05-11150-DPW

Abbott Laboratories' List of Agreed To Trial Exhibits

Trial Exhibit No.	Date	Production Range	Deposition Exhibit No.	Description
760	12/10/2001	ABBT209487 - ABBT209488	Leonard_0044	Summary of 12/10/2001 PEC Meeting
761	1/7/2002	ABBT0559668 - ABBT0559670	Leonard_0049	Interoffice correspondence re: summary on development status of ABT-773
762	11/27/2000	AUDIT 002817 - AUDIT 002829		Memorandum re: Meeting Minutes
763	4/12/2004	ABBT0000042 - ABBT0000045		Blewitt Letter re: Research Funding Agreement Dated 03/13/01
764	5/3/2004	ABBT0000046 - ABBT0000047		Desideri Letter re: Research Funding Agreement Dated 03/13/01
765	5/6/2004	ABBT0000049 - ABBT0000050		Davis Letter re: Research Funding Agreement Dated 03/13/01
766	5/11/2004	ABBT0000059 - ABBT0000060		Davis Letter re: Research Funding Agreement Dated 03/13/01
767	6/16/2004	ABBT0000079 - ABBT0000081		Davis Letter re: Research Funding Agreement Dated 03/13/01
768	1/28/2005	ABBT0000167 - ABBT0000168		D'Amore Letter re: Research Funding Agreement Dated 03/13/01
769	3/29/2005	ABBT0000216 - ABBT0000216		D'Amore Email re: John Hancock/Abbott - Audit Issues
770	4/21/2005	ABBT0000221 - ABBT0000222		D'Amore Letter re: Research Funding Agreement Dated 03/13/01
771	3/23/2004			Joint Statement Pursuant to Local Rule 16.1
772	00/00/0000	JH002310 - JH002311		Research and Development Transaction Investment Analysis
773	9/28/2001	ABBT0014648 - ABBT00146657		ABT518 Selective Matrix Metalloproteinase MMP Inhibitor
774	09/00/2001	ABBT0000381 - ABBT0000388		ABT-518 Matrix Metalloproteinase Inhibitor
775	2/23/2006	ABBT0014490 - ABBT0014491		Project Overview ABT-518 Closed ABT518 Previously in Ph 1
776	7/2/2001	ABBT290799 - ABBT290837		Kowaluk Email re: Final 07/03/2001 Update
777	9/19/2001	ABBT0046856 - ABBT0046891		Community Pharma Portfolio Senior Management Data Review 09/19/2001 Summary Materials; Development Assets Phase 2 Probability of Technical Success
778	4/4/2001	ABBT317223 - ABBT317239		Portfolio Analysis Review of Technical and Regulatory Success Probabilities
779	04/00/2001	ABBT0032090 - ABBT0032663		Portfolio Analysis April 2001 Review PPD and Knoll Assets Reference Materials
780	11/29/2000	ABBT0556816 - ABBT0556822	Fox_0004	Fox Email re: Slides for 12/5 Leiden meeting

John Hancock Life Insurance Company, et al. v Abbott Laboratories
Civil Action No. 05-11150-DPW

Abbott Laboratories' List of Agreed To Trial Exhibits

Trial Exhibit No.	Date	Production Range	Deposition Exhibit No.	Description
781	11/28/2000	ABBT0558150	Fox_0006	Fox Email re: Executive Summary of ABT-773 End-of-Phase 2 Mtg w/FDA
782	3/7/2001	ABBT0064316 - ABBT0064330		Abbott Portfolio Review March 7-9, 2001
783	00/00/0000	ABBT0007038 - ABBT0007054		Handwritten Notes and related documents to Discussion with Blewitt
784	8/21/2001	ABBT0184372 - ABBT0184496	Leiden_0032	ABT-594 Pharma Executive Management Committee Review
785	03/00/2001	ABBT0155581 - ABBT0155587		McKinsey Initial Portfolio Prioritization
786	1/28/2002	ABBT0578006 - ABBT0578015		Pharmaceutical Products R&D Global Discovery Project Expense Report
787	12/05/2000	ABBT205088 - ABBT205256		ABT773 Portfolio Review 12/05/2000
788	07/25/2001	ABBT119362.ur - ABBT119446.ur		ABT773 Dosing Options 07/25/2001
789	10/00/2001	ABBT0000726 - ABBT0000735		Monthly Status Project Report for ABT773 Ketolide Antibiotic Tablet, October 2001
790	03/00/2002	ABBT0000962 - ABBT0000971		Monthly Status Project Report for ABT773 Ketolide Antibiotic Tablet, March 2002
791	00/00/2001	ABBT112985.ur - ABBT112992.ur; ABBT112995.ur - ABBT112999.ur; ABBT113015.ur - ABBT113018.ur; ABBT113026.ur - ABBT113029.ur	Woidat_0009	Plan Assumption Memo Pass 3
792	05/23/2001	ABBT0001749 - ABBT0001758	Meyer_0020	M99-114 Study Review Presentation
793	00/00/2001	ABBT0556350 - ABBT0556356		Abstracts from 2001 ASCO Annual Meeting
794	00/00/0000	JH002424 - JH002429	Blewitt_0012	John Hancock Abbott Laboratories Research and Development Transaction
795	7/31/2001	ABBT0065982 - ABBT0066097		Clinical Study Report No. R&D/01/171 ABT-594 Protocol M99-114
796	01/00/2002	ABBT225522 - ABBT225529		ABT-773 Presentation for Miles White

John Hancock Life Insurance Company, et al. v Abbott Laboratories
Civil Action No. 05-11150-DPW

Abbott Laboratories' List of Agreed To Trial Exhibits

Trial Exhibit No.	Date	Production Range	Deposition Exhibit No.	Description
797	9/26/2002	ABBT240985 - ABBT241001		Report re: Randomized Double Blind Placebo Controlled Evaluation of the Safety and Efficacy of ABT-594
798	4/20/2004	ABBT0036399 - ABBT0036399; ABBT0008949 - ABBT0008949	Campbell_0003	Wittenberg Email re: Meeting for Hancock Audit with Wittenberg, Stiles, and Potthoff
799	6/22/2001	ABBT203851 - ABBT203894	Bukofzer_0015	Bukofzer Email re: attaching Final Copy of 773 Decision Analysis
800	03/00/2001	ABBT0047890 - ABBT0047892		Summary of Success Probabilities by Project and Franchise Portfolio Analysis (March 2001)
801	4/20/2001	ABBT0013874 - ABBT0013946		Portfolio Analysis of 2001 Abbott Global Pharmaceutical Development Assets
802	3/24/1999	JHII012355 - JHII012367	Klotz_0006	Purchase Recommendation for Idun Pharmaceuticals Inc. (Klotz 6)
803	7/3/2000	JH003032 - JH003057	Klotz_0009	Klotz Email re: Update on Cytostatic Area (Klotz 9)
804	7/11/2000	JH003007 - JH003013	Klotz_0014	Klotz Email re: Edit of Neuropathic Pain Summary (Klotz 14)
805	7/28/2000	JH002973 - JH002979	Klotz_0015	Klotz Email re: Abbott Interview Writeup (Klotz 15)
806	9/21/2000	JH001203 - JH001220	Klotz_0017	Purchase Recommendation for Abbott Laboratories (Klotz 17)
807	02/00/2001	JH008153 - JH008209	Klotz_0019	ABT-773 Descriptive Memorandum February 2001 (Klotz 19)
808	05/00/2000	ABBT246466 - ABBT246471	Klotz_0020	ABT-773 Descriptive Memorandum May 2000 (Klotz 20)
809	00/00/2000	JH002212 - JH002226	Klotz_0021	Pub Med Abstracts re: ABT- 773 (Klotz 21)
810	00/00/0000	JH000655 - JH000658	Klotz_0025	List of Questions for Interviewees re: ABT-773 (Klotz 25)
811	7/21/2000	JH002993 - JH002997	Klotz_0027	Klotz Email re: Moellering Interview (Klotz 27)
812	3/7/2000	JH002308 - JH002311	Nataou_0001	Agreement re: Proposed Summary of Terms (Nastou 1)
813	5/8/2000	JH002423 - JH002429	Nastou_0002	Blewitt Memo re: Proposed John Hancock Abbott Laboratories Transaction (Nastou 2)
814	9/21/2000	JH001185 - JH001202	Nastou_0006	Purchase Recommendation for Abbott Laboratories (Nastou 6)
815	9/21/2000	JH005573 - JH005573	Nastou_0007	Bond Investment Committee Meeting (Nastou 7)

John Hancock Life Insurance Company, et al. v Abbott Laboratories
Civil Action No. 05-11150-DPW

Abbott Laboratories' List of Agreed To Trial Exhibits

Trial Exhibit No.	Date	Production Range	Deposition Exhibit No.	Description
816	10/10/2000	JH005551 - JH005553	Nastou_0008	Committee of Finance Records (Nastou 8)
817	9/30/2002	JH003142 - JH003158	Blewitt_0013	Blewitt Email forwarding the latest model re: Abbott Labs (Blewitt 13)
818	7/11/2000	JH003014 - JH003026	Blewitt_0017	Klotz Email attaching research summaries (Blewitt 17)
819	7/18/2000	JH002999 - JH003001	Blewitt_0018	Klotz Email First neuropathic pain interview (Blewitt 18)
820	3/13/2001	JH008076 - JH008211	Blewitt_0020	Research Funding Agreement by and between Abbott Laboratories and John Hancock Life Insurance Co. (Blewitt 20)
821	6/5/2000	ABBT246466 - ABBT246471	Blewitt_0032	ABT-773 Descriptive Memorandum 05/00/2000 (Blewitt 32)
822	00/00/0000	JH000655 - JH000658	Blewitt_0038	List of Questions for Interviewees re: ABT-773 (Blewitt 38)
823	7/21/2000	JH002993 - JH002997	Blewitt_0039	Klotz Email Moellering Interview (Blewitt 39)
824	7/28/2000	JH002973 - JH002979	Blewitt_0041	Klotz Email re Abbott Interview Writeup (Blewitt 41)
825	02/00/2001	ABBT0000343 - ABBT0000348	Nisen_0002	February 2001 Project Status Report for ABT-518 Matrix Metalloproteinase Inhibitor (Nisen 2)
826	08/00/2000	ABBT256634 - ABBT256645	Nisen_0005	ABT-518 Transition Strategy MMPI Report (Nisen 5)
827	02/00/2001	ABBT0004032 - ABBT0004039	Nisen_0010	ABT-518 Descriptive Memorandum February 2001 (Nisen 10)
828	3/9/2001	ABBT0013224 - ABBT0013232	Nisen_0011	Abbott Portfolio Review 03/07/2001 to 03/09/2001 Presentation (Nisen 11)
829	8/14/2001	ABBT0049980 - ABBT0049981	Nisen_0032	Nisen Memo re: ABT-518 (Nisen 32)
830	9/23/2002	ABBT334838 - ABBT334841	Nisen_0037	Kirkpatrick Email re: Status of JH Compounds Divestment Activities (Nisen 37)
831	5/22/2001	ABBT0064226 - ABBT0064226	Nisen_0038	Nisen Email re: ABT-518 Summary of Findings on MMPI (Nisen 38)
832	5/28/2001	ABBT0033486 - ABBT0033494	Nisen_0039	Bronson Email re: ABT-518 Slides Whoops (Nisen 39)
833	6/11/2001	ABBT0063625 - ABBT0063626	Nisen_0040	Nisen Email re: MMPI Data from Subject X Additional Info (Nisen 40)

John Hancock Life Insurance Company et al. v Abbott Laboratories
Civil Action No. 05-11150-DPW

Abbott Laboratories' List of Objected To Trial Exhibits

Trial Exhibit No.	Date	Production Range	Deposition Exhibit No.	Description	Hancock Objections
D_A	11/00/2000	ABBT0006627 - ABBT0006700		Cohen Memo Attaching Diligence and Research Plan	Authenticity / Hearsay (ABBT0006627-8)
D_B	00/00/0000	AND00001 - AND00015	Andrews_0004	Presentation titled "NNRs and Pain: NNRs are Expressed in Pain Pathways" (Andrews 4)	Authenticity
D_C	7/11/2002	ABBT203446 - ABBT203450		Bukofzer Email re: ABT 773 Communication	Multiple Documents / Hearsay (ABBT203449-50)
D_D	00/00/2001	JH001446 - JH001459		DiMasi Article titled "Success Rates for New Drugs Entering Clinical Testing in the US"	Hearsay
D_E	3/24/1999	JH0012355 - JH0012367; JH003080; JH002081 - JH002090	Blewitt_0005	Purchase Recommendation re: Idun Pharmaceuticals Inc. (Blewitt 5)	Multiple Documents
D_F	6/29/1999	ABBT0020546 - ABBT0020551	McCarthy_0004	Lai Email re: ABT-259 Summary Statement Draft # 2 (McCarthy 4)	Hearsay
D_G	11/21/1999	JH000767 - JH000770		Nadler Article titled "New Antimicrobials: Facing Our Problems"	Hearsay / Irrelevant
D_H	00/00/2000		Klotz_0030	DePonti, Poluzzi & Montanero Article titled "QT Interval Prolongation by Non Cardiac Drugs Lessons to be Learned from Recent Experience"	Hearsay / Irrelevant
D_I	5/9/2000	ABBT242357 - ABBT242361	Collicut_0001	Collicott Email re: Resume	Hearsay / Irrelevant / Authenticity
D_J	5/11/2000	JH000747 - JH000761		Ketek Profile	Hearsay / Irrelevant
D_K	6/20/2000	ABBT0510354 - ABBT0510483		Study Report No. R&D/99/280 for ABT-594 Protocol M98833 June 20, 2000	Irrelevant
D_L	07/00/2000		Klotz_0028	Research Analysis Report by Wiqar Shaik Titled, "The Changing Face of Antihistamines and Cardiac Adverse Drug Reactions: A Clinical Perspective"	Hearsay / Irrelevant
D_M	8/11/2000		Klotz_0029	MedWatch Summary of Safety Related Drug Labeling Changes Approved by FDA June 2000	Hearsay / Irrelevant
D_N	9/15/2000	ABBT242156 - ABBT242156		Collicott Email re: ABT-594 Phase IIb Meeting	Hearsay
D_O	10/10/2000	JH002373 - JH002390		Redacted version of Purchase Recommendation re: Abbott Labs ("Non-Recourse") with handwritten notes	Authenticity
D_P	10/26/2000	JH007701 - JH007701		Pals Email re: Hancock [Information Regarding the Two Websites]	Hearsay
D_Q	11/1/2000	JH003740 - JH003814		Tormey Email re: Funding Agreement	Irrelevant
D_R	11/10/2000	JH005273 - JH005348	Tormey_0011	Tormey Email re: Research Funding Agreement (Tormey 11)	Irrelevant
D_S	11/28/2000	ABBT314979 - ABBT314987	McCarthy_0031	Kuemmerle Email re: Neuroscience Portfolio Working Session for 11/21/0000: Technical Assessment (Silber 32, McCarthy 31)	Hearsay
D_T	00/00/2001	ABBT0010550 - ABBT0010576		2001 Portfolio Worksheets	Hearsay (ABBT0010574)

John Hancock Life Insurance Company et al. v Abbott Laboratories
Civil Action No. 05-11150-DPW

Abbott Laboratories' List of Objected To Trial Exhibits

D_D	00/00/2001	JH001446 - JH001459		DiMasi Article titled "Success Rates for New Drugs Entering Clinical Testing in the US"	Hearsay
D_U	2/2/2001	ABBT292664 - ABBT294198		Dart Email re: Probabilities [Update Regarding the R&D Sheets]	Hearsay
D_V	2/15/2001	JH006299 - JH006359		Pals Email re: Research Funding Agreement	Hearsay / Irrelevant
D_W	2/28/2001	ABBT0576918 - ABBT0576923		Report re: CLARITHROMYCIN Japan Update 02/00/2001 Current Drug Development	Hearsay
D_X	3/9/2001	JH008376 - JH008384		Lee facsimile re: Research Funding Agreement Draft	Irrelevant / Hearsay
D_Y	3/13/2001	JH008074 - JH008211		Research Funding Agreement between Abbott Laboratories and John Hancock Life Insurance	Multiple Documents; JH008074-75: Irrelevant; JH008076-21: No Objection
D_Z	3/16/2001	ABBT0012388 - ABBT0012390	Deemer_0017	Baker Email re: Revisions to the Oncology Portfolio Analysis Information (Deemer 17)	Hearsay / Authenticity
D_AA	3/26/2001	ABBT360531 - ABBT360573		Woidat Email re: 773 Presentation	Hearsay
D_AB	4/3/2001	ABBT0033510 - ABBT0033516		Kowaluk Email re: Oncology Probabilities Revised	Hearsay
D_AC	4/27/2001	ABBT110591.ur - ABBT110591.ur		Fox Email re: FYI Ketek	Hearsay
D_AD	5/4/2001	ABBT0054230 - ABBT0054231		Hansen Email re: Marimastat	Hearsay
D_AE	5/9/2001	ABBT294559 - ABBT294560		Kowaluk Email re: ABT-594 Pain DSG	Hearsay
D_AF	5/21/2001	ABBT0164581 - ABBT0164581		McCarthy Email re: ABT-594 Advisory Meeting?	Hearsay
D_AG	6/7/2001	ABBT0054387 - ABBT0054387		D'Amico Email re: Update	Hearsay
D_AH	7/9/2001	ABBT288530 - ABBT288530		Kowaluk Email re: 594 GPEC Prep	Hearsay
D_AI	7/13/2001	ABBT209793 - ABBT209829		Kuemmerle Email re: ABT-773 Analysis: Reminder	Hearsay (ABBT209793-4)
D_AJ	8/6/2001	ABBT0049990 - ABBT0049990		Davidson Email to Nisen re: ABT-518 [Marimastat Shows Promise as Treatment for Unresectable Pancreatic Cancer]	Hearsay
D_AK	8/16/2001	ABBT289332 - ABBT289344	McCarthy_0053	Kowaluk Email re: ABT-594 DSG Slides for PEMC Review (McCarthy 53)	Hearsay (ABBT289332)
D_AL	9/20/2001	ABBT203477 - ABBT203484		C. Meyer Email thread re: Portfolio issues update	Hearsay
D_AM	10/2/2001	ABBT201003 - ABBT201007	McCarthy_0057	Leonard Memo re: 10/08 PEC Meeting Agenda	Hearsay (ABBT201003)
D_AN	10/9/2001	ABBT246335 - ABBT246335	Kowaluk_0030	Biarnesen Email re: ABT-594 Project Team Update	Hearsay
D_AO	7/11/2002	ABBT203446 - ABBT203453		Bukofzer Email re: ABT-773 Communication	Hearsay
D_AP	8/6/2002	ABBT333998 - ABBT333998		Lyons Email re: ABT-773	Hearsay
D_AQ	9/26/2002	AUDIT 002790 - AUDIT 002790		Elitra Pharmaceuticals ABT-773 Non-Binding Letter of Intent 09/26/02	Hearsay / Authenticity
D_AR	10/16/2002	AUDIT 002791 - AUDIT 002793		Letter of Intent between Elitra Pharmaceuticals and Abbott Laboratories	Hearsay
D_AS	12/6/2002	ABBT0518032 - ABBT0518034		Tyree Memo re: November 2002 Highlights	Hearsay
D_AT	12/20/2002	JH009977 - JH009978		Johansson Letter re: Research Funding Agreement Dated as of 03/31/01	Hearsay
D_AU	12/20/2002	JH000807 - JH000817	Hendrick_0008	Lyons Letter re: Research Funding Agreement Dated as of 03/13/01 (a) 2002 Program Status Report and Related Cost Summary (b) 2003 Preliminary Annual Research Plan (Hendricks 8)	Hearsay
D_AV	2/28/2003	ABBT335048 - ABBT335050		Mathers Letter re: February Highlights	Hearsay
D_AW	11/12/2003	ABBT0004519 - ABBT0004520		Tyree Letter re: Research Funding Agreement Dated 03/13/01	Used in Settlement Discussions and inadmissible under Fed. R. Evid. 408

John Hancock Life Insurance Company et al. v Abbott Laboratories
Civil Action No. 05-11150-DPW

Abbott Laboratories' List of Objected To Trial Exhibits

D_D	00/00/2001	JH001446 - JH001459		DiMasi Article titled "Success Rates for New Drugs Entering Clinical Testing in the US"	Hearsay
D_AX	00/00/2004	CRA00127 - CRA00139		Hancock Program Funding Scenarios (Work Paper)	Hearsay
D_AY	5/10/2004	ABBT0000057 - ABBT0000058		Desideri Letter re: Research Funding Agreement Dated 03/13/01	Hearsay
D_AZ	5/18/2004	ABBT0000061 - ABBT0000064		Facsimile of Desideri Letter re: Research Funding Agreement Dated 03/13/01	Hearsay
D_BA	6/10/2004	ABBT0190551 - ABBT0190552		Pavelske Email re: RICs boxes, Hancock audit	Hearsay
D_BB	6/15/2004	ABBT0000077 - ABBT0000078		Desideri Letter re: Research Funding Agreement Dated 03/13/01	Hearsay
D_BC	8/5/2004	ABBT0000125 - ABBT0000127		Desideri Letter re: Research Funding Agreement Dated 03/13/01	Hearsay
D_BD	9/9/2004		Blewitt_0021	Affidavit of Stephen J. Blewitt (Blewitt 21)	Hearsay
D_BE	10/27/2004	JHII011289 - JHII011291		Johansson Letter re: Research Funding Agreement Dated as of 03/31/01	Hearsay
D_BF	12/2/2004	JHII011295 - JHII011295		Tyree Letter re: Research Funding Agreement Dated 03/13/01	Hearsay
D_BG	12/3/2004	ABBT0126668 - ABBT0126669		Wittenberg Email re: John Hancock/Abbott	Hearsay
D_BH	9/6/2005	JHII012056 - JHII012061	Blewitt_0030	Blewitt Memo re: Report Request # 85 (FOLLOW-UP) - Valuation of Sch BA Part 1 Assets Abbott Laboratories (Blewitt 30)	Hearsay
D_BI	12/6/2005	JHII012050 - JHII012055		Investment Review Report re: Execution Version of Agreement	Hearsay
D_BJ	5/25/2007		Fairweather_0003	Reece Letter re: John Hancock Life Insurance Co et al v Abbott Laboratories Civil Action Number 0511150DPW (Fairweather 3)	Hearsay
D_BK	5/29/2007		Fairweather_0002	Flower Valley Consulting Inc. Web Article titled "Good Statistics Don't Happen by Chance" (Fairweather 2)	Hearsay
D_BL	5/29/2007		Gold_0002	Edelstein Letter Forwarding List of Documents Relied Upon by Gold (Gold 2)	Hearsay / Irrelevant
D_BM	5/29/2007		Gold_0003	Edelstein Letter Forwarding 2 Documents Relied Upon by Gold (Gold 3)	Hearsay
D_BN	10/13/2006		Rodda_0003	Expert Report of Dr. Bruce Rodda	Hearsay
D_BO	10/13/2006		Friedman_0001	Expert Report of Alan Friedman	Hearsay
D_BP	1/19/2007		Tucker_0002	Expert Report of Avram S. Tucker	Hearsay
D_BQ	2/20/2007			Life Science Weekly Article titled, "Recent Reports from Advanced Life Sciences Holdings provided and update"	Hearsay
D_BR	2/26/2007		Rodda_0002	Expert Report of Dr. Bruce Rodda (Statistical Issues)	Hearsay
D_BS	6/11/2007			Crain's Chicago Business Article titled, "Waiting to Exhale. Day of Reckoning nears as biotech firm Advanced Life awaits trial results on new treatment for pneumonia" by Mike Colias	Hearsay
D_BT	6/21/2007			Advanced Life Sciences News Release titled, "Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial"	Hearsay

John Hancock Life Insurance Company et al. v Abbott Laboratories
Civil Action No. 05-11150-DPW

Abbott Laboratories' List of Objected To Trial Exhibits

D_D	00/00/2001	JH001446 - JH001459		DiMasi Article titled "Success Rates for New Drugs Entering Clinical Testing in the US"	Hearsay
D_BU	6/29/2007			Crain's Chicago Business Article titled, "Waiting to Exhale. Clinical Trials" by Mike Colias	Hearsay
D_BV	8/15/2007			Sanofi-Aventis February 2007 internet Ketek product description	Hearsay
D_BW	8/15/2007			U.S. Food and Drug Administration Center for Drug Evaluation and Research Web Page Article titled, "Drug-Induced Liver Toxicity"	Hearsay
D_BX	08/21/2007			Life Science Weekly Article titled, "Reports from Advanced Life Sciences Holdings describe recent developments"	Hearsay
D_BY	12/3/2007			Supplemental Expert Report of Avram S. Tucker	Hearsay
D_BZ	12/12/2003			Complaint in <i>Hancock Life Ins. Co., et al. v. Abbott Laboratories</i> , No. 03-12501 (<i>Hancock I</i>)	Irrelevant
D_CA	6/3/2004	ABBT0000071 - ABBT0000073		Desideri Letter re: Research Funding Agreement Dated 03/13/01	Hearsay
D_CB	6/16/2004			D'Amore Letter re: Hancock v. Abbott	Hearsay
D_CC	6/18/2004			D'Amore Letter re: Hancock v. Abbott	Hearsay
D_CD	6/30/2004			D'Amore Letter re: Hancock v. Abbott	Hearsay
D_CE	8/24/2004			Desideri Letter re: Research Funding Agreement Dated 03/13/01	Hearsay
D_CF	9/29/2004			September 29, 2004 Affidavit of Stephen J. Blewitt	Hearsay
D_CG	2/11/2005			D'Amore Letter re: Research Funding Agreement Dated 03/14/01	Hearsay
D_CH	2/15/2005			D'Amore Letter re: Research Funding Agreement Dated 03/14/01	Hearsay
D_CI	6/3/2005			Complaint	Irrelevant
D_CJ	7/29/2005			Answer to Complaint	Hearsay
D_CK	10/13/2005			Transcript of Court's Status Conference Hearing	Hearsay
D_CL	11/7/2005			Abbott's Response to Hancock's First Request for Production of Documents	Hearsay
D_CM	11/28/2005			D'Amore Letter re: Hancock v. Abbott, Case No. 05-11 I50-DPW	Hearsay
D_CN	12/9/2005			D'Amore Letter re: Hancock v. Abbott, Case No. 05-11 I50-DPW	Hearsay
D_CO	3/28/2006			Applied Discovery, Inc. Letter reflecting production of Bates Range ABBT200001- ABBT367508	Hearsay / Authenticity
D_CP	6/23/2006		Friedman_0002	Supplemental Complaint	Irrelevant
D_CQ	7/13/2006		Klaus_0004A	Abbott's Supplemental Responses and Objections To Plaintiffs' Rule 30(b)(6) Deposition Notice (Audit)	Hearsay
D_CR	12/6/2006			Transcript of Hearing before Honorable Douglas P. Woodlock	Hearsay
D_CS	12/29/2006			First Amended Supplemental Complaint	Irrelevant
D_CT	1/12/2007			Answer to Amended Complaint (Docket # 107)	Irrelevant
D_CU	3/6/2007			Guzelsu Letter enclosing documents	Hearsay
D_CV	6/4/2007			Lorenzini Email re: interrogatory responses	Hearsay
D_CW	10/25/2007			Transcript of Pre-trial Conference	Hearsay
D_CX	11/8/2007			Davis Letter attaching chart	Irrelevant

John Hancock Life Insurance Company et al. v Abbott Laboratories
Civil Action No. 05-11150-DPW

Abbott Laboratories' List of Objected To Trial Exhibits

D_D	00/00/2001	JH001446 - JH001459		DiMasi Article titled "Success Rates for New Drugs Entering Clinical Testing in the US"	Hearsay
D_CY	11/15/2007			Lorenzini Email attaching Redline comparing First Amended Complaint to Second Amended Complaint	Irrelevant
D_CZ	11/29/2007			Answer to Amended Complaint (Docket # 204)	Irrelevant
D_DA	4/6/2001	ABBT0176908 - 0176909		Rieser Email re: Azmi's Weekly Update	Hearsay
D_DB	12/11/2000	ABBT0125549		Calendar Entry Meeting ABT- 594 Power Calculations with Siber, Morris, Leonard	Hearsay
D_DC	5/23/2001	ABBT354519 - ABBT354520		Woidat Email re: ABT-594 2001 Budget	Hearsay
D_DD	8/16/2001	ABBT0048631		Interoffice memorandum re: ABT-594 Review, August 21, 2001, Pharmaceutical Executive Management Committee	Hearsay
D_DE	8/7/2001	ABBT0120919 - ABBT0120921		Wise Email re: PEMC 8/21 Agenda	Hearsay
D_DF	10/5/2001	ABBT224537 - ABBT224539		Leonard Email re: New Agenda for Monday's PEC Meeting	Hearsay
D_DG	10/5/2001	ABBT0111238 - ABBT0111240		Chiozzi Email re: October 8 program	Hearsay
D_DH	10/8/2001	ABBT334009 - ABBT334011		Interoffice memorandum re: Monthly Highlights - September 2001	Hearsay
D_DI	10/18/2001	ABBT304685		Kowaluk Email re: Highlights	Hearsay
D_DJ	11/15/2001	ABBT0165160 - ABBT0165162		McCarthy Email re: 2002 Goals	Hearsay
D_DK	2/14/2003	ABBT0009617 - ABBT0009618		Out-license Anti-infective Compounds Board Document February 14, 2003 Draft 8	Authenticity / Hearsay
D_DL	3/27/2001	ABBT327314 - ABBT327327		Kowaluk Email re: therapeutic strategy evaluations attaching briefing document portfolio review	Hearsay (ABBT327316-27)
D_DM	12/12/2000	ABBT0569030		Calendar Entry Rescheduled Meeting ABT- 773 Project Review	Hearsay
D_DN	4/27/2001	ABBT143066.ur - ABBT143067.ur		Interoffice Memorandum re: Monthly Highlights April 2001	Hearsay
D_DO	8/10/2001	ABBT0003466 - ABBT0003467		Interoffice Memorandum re: Monthly Highlights July 2001	Hearsay
D_DP	10/8/2001	ABBT0003482 - ABBT0003484		Interoffice Memorandum re: Monthly Highlights September 2001	Hearsay
D_DQ	1/9/2002	ABBT0569033		Calendar Entry Meeting ABT- 773 Presentation	Hearsay
D_DR	2/8/2002	ABBT247733 - ABBT247737		Interoffice Memorandum re: Monthly Highlights January 2002	Hearsay
D_DS	4/9/2002	ABBT103547.ur - ABBT103551.ur		Interoffice Memorandum re: Monthly Highlights March 2002	Hearsay
D_DT	1/18/2001	ABBT0064814 - ABBT064817		Nisen Email re: Goodwin Philanthropy	Hearsay / Irrelevant
D_DU	11/1/2000	ABBT0107162		Silber Email re: Pharmacia meeting	Hearsay
D_DV	1/9/2002	ABBT0569033		Calendar entry - Meeting re: ABT-773 Presentation to Miles White	Hearsay
D_DW	3/30/2004			Transcript of March 30, 2004 Hearing in Hancock I	Hearsay
D_DX	6/15/2004	ABBT0000077 - ABBT0000078		Desideri Letter re: Research Funding Agreement Dated 03/13/01	Hearsay
D_DY	2/11/2005	ABBT0000182 - ABBT0000183		D'Amore Letter re: Research Funding Agreement Dated 03/14/01	Hearsay
D_DZ	2/11/2005	ABBT0000038 - ABBT0000040		Davis Letter re: Research Funding Agreement Dated 03/13/01	Irrelevant

John Hancock Life Insurance Company et al. v Abbott Laboratories
Civil Action No. 05-11150-DPW

Abbott Laboratories' List of Objected To Trial Exhibits

D_D	00/00/2001	JH001446 - JH001459		DiMasi Article titled "Success Rates for New Drugs Entering Clinical Testing in the US"	Hearsay
D_EA	2/15/2005	ABBT0000187 - ABBT0000188		D'Amore Letter re: Research Funding Agreement Dated 03/14/01	Hearsay
D_EB	2/15/2005	ABBT0000189 - ABBT0000190		Davis Letter re: Research Funding Agreement Dated 03/13/01	Hearsay
D_EC	12/00/2001	ABBT120514.ur - ABBT120558.ur		December 2001 PEC Presentation re ABT-773	Irrelevant
D_ED	7/30/2002	JH001097 - JH001100		Notice of Termination of ABT-773 Hancock Notes	Authenticity / Irrelevant / Hearsay
D_EE	1/9/2008			Poulos letter re: Research Funding Agreement Update Correction	Hearsay
D_EF	8/22/2001	ABBT246353 - ABBT246368		Deemer Email re: outlicensing opportunities attaching introductory slides	Hearsay / Authenticity
D_EG	9/28/2001	ABBT246248 - ABBT24652		Deemer Email re: Deemer Weekly Update	Hearsay
D_EH	10/12/2001	ABBT246369		Deemer Email re: Licensing opportunities	Hearsay
D_EI	10/26/2001	ABBT0086829		Rosenthal Email re: ABT-518 and hematological cancer	Hearsay
D_EJ	10/24/2001	ABBT246338 - ABBT24644		Deemer Email re: Update of ETAs Priority 1	Hearsay
D_EK	1/25/2002	ABBT0065300 - ABBT0065335		Nisen Email re: Goodwin Slides	Hearsay / Irrelevant
D_EL	4/3/2002	ABBT0170011 - ABBT0170014		Hoff-Velk Email re: Salmedix ABT-518	Hearsay
D_EM	4/6/2002	ABBT0141755 - ABBT0141772		ABT-518 Selective Matrix Metalloproteinase MMP Inhibitor	Hearsay
D_EN	4/16/2002	ABBT0089655		Hoff-Velk Email re: Salmedix Forwarding Jerrys Note	Hearsay
D_EO	5/3/2002	ABBT0542887 - ABBT0542892		Poulos Email re: April highlights	Hearsay
D_EP	8/2/2002	ABBT0086988		Fitzgerald Email re: ABT-518 Outlicense Status	Hearsay
D_EQ	8/13/2002	ABBT0169420 - ABBT0169421		Nabulsi Email re: John Hopkins Cancer Center and Abbott Oncology Collaboration Meeting	Hearsay
D_ER	8/14/2002	ABBT0141711 - ABBT0141728		Johns Hopkins 8-02.PPT; ABT-518 Selective Matrix Metalloproteinase MMP Inhibitor	Hearsay
D_ES	9/24/2003	ABBT0091538 - ABBT0091539		Hoff-Velk Email re: ABT-518 forwarding Prospective Licensee	Hearsay
D_ET	2/20/2004	ABBT0167630 - ABBT0167638		Asia Trip Report, Feb. 16-20, 2004, Perry Nisen	Hearsay
D_EU	5/25/2004	ABBT0089550 - ABBT0089551		Davidson Email re: ABT518 Negative Clinical Results with AG3340 and Marimastat	Hearsay
D_EV	5/31/2001	ABBT0060145		Jansen Email re: M00235 Enrollment	Hearsay
D_EW	4/9/2001	ABBT285535 - ABBT285536		Kowaluk Email re: Portfolio Probabilities	Hearsay
D_EX	1/25/2001	ABBT301935 - ABBT301941	Kowaluk_0010	Kowaluk Email re: Summary of Success Probabilities	Hearsay (ABBT301935)
D_EY	9/19/2001	ABBT0046892 - ABBT0046902		Pain Table of Contents	Irrelevant
D_EZ	00/00/2000	JHII021962 - JHII021979		Monte Carlo Analysis Work Paper	Hearsay / Irrelevant
D_FA	11/7/2002	ABBT352502 - ABBT352504		08/00/2005 Highlights	Hearsay
D_FB	00/00/0000	JH006641 - JH006643		John Hancock Development Portfolio Annual Progress Report	Hearsay / Authenticity / Incomplete / Irrelevant

John Hancock Life Insurance Company et al. v Abbott Laboratories
Civil Action No. 05-11150-DPW

Abbott Laboratories' List of Objected To Trial Exhibits

D_D	00/00/2001	JH001446 - JH001459		DiMasi Article titled "Success Rates for New Drugs Entering Clinical Testing in the US"	Hearsay
D_FC	1/20/2003	ABBT0578016 - ABBT0578022		Pharmaceutical Products R&D Global Discovery Project Expense Report	Irrelevant
D_FD	12/00/2002	ABBT0578023 - ABBT0578025		Comprehensive Project Accounting System DINGII Project Detail 12/00/2002	Irrelevant
D_FE	6/7/2004	ABBT0578026 - ABBT0578031		Global Pharmaceutical Research and Development Global Development Project Expense Report Site Global All Sites 12/00/2003	Irrelevant
D_FF	1/14/2005	ABBT0578032 - ABBT0578035		Global Pharmaceutical Research and Development Global Development Project Expense Report Site Global All	Irrelevant
D_FG	12/00/2005	ABBT0578036 - ABBT0578038		Global Pharmaceutical Research and Development Global Development Project Expense Report Site Global All	Irrelevant
D_FH	12/00/2001	ABBT0578039 - ABBT0578057		Compass Comprehensive Project Accounting System Dingh Project Detail	Hearsay / Authenticity / Irrelevant
D_FI	05/00/2001	ABBT0556331 - ABBT0556331		Phase 2 Study of the Matrix Metalloprotease Inhibitor Prinomastat in Patients with Progressive Breast Cancer	Hearsay / Authenticity
D_FJ	5/14/2001	ABBT0556334 - ABBT0556349		Handwritten notes re: American Society of Clinical Oncology SF	Hearsay / Authenticity
D_FK	00/00/2001	ABBT0556332 - ABBT0556333		Abstracts from Proceedings of ASCO Volume 20, 2001	Hearsay / Authenticity
D_FL	10/19/2000	ABBT0061747 - ABBT0061748		Kysa Email re: MMPI press release	Incomplete / Hearsay
D_FM	11/3/2000	ABBT0057776 - ABBT0057777; ABBT0057787 - ABBT0057843		Davidson Email re: JCO paper on Bayer compound	Multiple Documents / Hearsay
D_FN	3/5/2001	ABBT0026863 - ABBT0026866		Drug document compound details for Marimastat	Hearsay
D_FO	8/3/2007			Abbott's Amended Responses and Objections to Hancock's 2nd Set of Interrogatories	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any
D_FP	5/1/2000	JH001691 - JH001693	Klotz_0001	Klotz Letter re: General Biotechnology and Pharmaceutical Investments Consulting (Klotz 1)	No Objection
D_FQ	2/5/2001	ABBT328810 - ABBT328812	McCarthy_0038	McCarthy Email re: DSG with reply by Kowaluk (McCarthy 38)	Hearsay
D_FR	10/23/2001	ABBT246791 - ABBT246792	McCarthy_0061	McCarthy Email re: Non Confidential Briefing on ABT-594 (McCarthy 61)	Hearsay
D_FS	3/14/2003	JH002447 - JH002447	Mastromarino_0001	Welch Email re: Abbott Labs (Mastromarino 1)	No Objection
D_FT	07/23/2001	ABBT103191.ur - ABBT103270.ur		ABT-773 Presentation	No Objection
D_FU	2/8/2002	ABBT0027417 - ABBT0027432		Turner Email attaching year end reports	Hearsay
D_FV	00/00/0000	ABBT0577855 - ABBT0577884		ABT-773 Out-licensing Documents	Multiple documents/Authenticity/Hearsay
D_FW	3/5/2003	JH002419 - JH002420		Mangan Email re: February Early Warning Projection	No Objection
D_FX	2/27/2006	JHII021946 - JHII021948		Hancock Loan Review Report	No Objection
D_FY	00/00/0000			Moody Rating Symbols & Definitions	Authenticity/Irrelevant
D_FZ	11/25/2007			ALS Press Release identified as Exhibit 99.1 to Advanced Life Sciences Form 8-K for the period of November 15, 2007	No Objection

John Hancock Life Insurance Company et al. v Abbott Laboratories
Civil Action No. 05-11150-DPW

Abbott Laboratories' List of Objected To Trial Exhibits

D_D	00/00/2001	JH001446 - JH001459		DiMasi Article titled "Success Rates for New Drugs Entering Clinical Testing in the US"	Hearsay
D_GA	1/28/2008			Affidavit of Alan Friedman dated January 28, 2008	Hearsay
D_GB	1/28/2008			Affidavit of Stephen Blewitt dated January 28, 2008	Hearsay
D_GC	10/12/2007			Affidavit of Keith Hendricks dated October 12, 2007	Hearsay
D_GD	10/23/2007			Supplemental Affidavit of Keith Hendricks dated October 23, 2007	Hearsay
D_GE	10/17/2000	AL000481 - AL000521	Blewitt_0022	Draft Research Funding Agreement by and between Abbott Laboratories and John Hancock Life Insurance Co Dated as of 10/00/2000 (Blewitt 22)	Irrelevant
D_GF	03/00/2001	AL001323 - AL001377	Blewitt_0023	Research Funding Agreement by and between Abbott Laboratories and John Hancock Life Insurance Co Dated as of 03/00/2001 (Blewitt 23)	Irrelevant
D_GG	5/11/2000	JH000747 - JH000761	Blewitt_0036	Ketek Profile Report (Blewitt 36)	Hearsay / Irrelevant
D_GH	12/20/2002	JH000807 - JH000817	Blewitt_0043	Letter re: research Funding Agreement Dated as of 03/13/2001 (Blewitt 43)	Hearsay
D_GI	8/10/2001	ABBT0049970 - ABBT0064233	Nisen_0031	Davidson Memo Results from the ABT-518 Clinical Trial (Nisen 31)	No Objection
D_GJ	4/10/2001	ABBT294218 - ABBT294247	Hopfield_0023	Redenbach - Mueller Email re: Fw Pharma Strategy Retreat Virus Checked (Hopfield 23)	Hearsay (ABBT294218-20)
D_GK	10/29/1999	ABBT335520 - ABBT335570	Collicott_0004	Abbott Laboratories ABT-594 Investigational New Drug IND Annual Report (Collicott 4)	No Objection
D_GL	11/00/2000	ABBT144600.UR - ABBT144609.UR	Collicott_0018	ABT-594 Descriptive Memorandum November 2000 (Collicott 18)	No Objection (PL's DL)
D_GM	01/18/2001	ABBT240417 - ABBT240417	Collicott_0030	Collicott Email re: ABT-594 Completion of Study for Neuropathic Pain (Collicott 30)	Hearsay
D_GN	4/23/2001	ABBT0001749 - ABBT0001758	Collicott_0039	M99114 Study Review Presentation (Collicott 39)	No Objection (PL's FN)
D_GO	00/00/2001	ABBT0003252 - ABBT0003254		ABT-751 Project Information Report	No Objection
D-GP	2/17/2008			Schedule 1A illustration of Impact of Selected Errors in Mr. Friedman's Lost Royalties and Milestone Payment Calculation - Low Case	Hearsay/Untimely
D_GQ	2/17/2008			Schedule 1B illustration of Impact of Selected Errors in Mr. Friedman's Lost Royalties and Milestone Payment Calculation - Base Case	Hearsay/Untimely
D_GR	2/17/2008			Schedule 2A illustration of Impact of Selected Errors in Mr. Friedman's Lost Royalties and Milestone Payment Calculation - Low Case	Hearsay/Untimely
D_GS	2/17/2008			Schedule 2B illustration of Impact of Selected Errors in Mr. Friedman's Lost Royalties and Milestone Payment Calculation - Base Case	Hearsay/Untimely
D_GT	2/17/2008			Schedule 3A illustration of Impact of Selected Errors in Mr. Friedman's Lost Royalties and Milestone Payment Calculation - Low Case	Hearsay/Untimely
D_GU	2/17/2008			Schedule 3B illustration of Impact of Selected Errors in Mr. Friedman's Lost Royalties and Milestone Payment Calculation - Base Case	Hearsay/Untimely

John Hancock Life Insurance Company et al. v Abbott Laboratories
Civil Action No. 05-11150-DPW

Abbott Laboratories' List of Objected To Trial Exhibits

D_D	00/00/2001	JH001446 - JH001459		DiMasi Article titled "Success Rates for New Drugs Entering Clinical Testing in the US"	Hearsay
D_GV	2/17/2008			Schedule 4A illustration of Impact of Selected Errors in Mr. Friedman's Lost Royalties and Milestone Payment Calculation - Low Case	Hearsay/Untimely
D_GW	2/17/2008			Schedule 4B illustration of Impact of Selected Errors in Mr. Friedman's Lost Royalties and Milestone Payment Calculation - Base Case	Hearsay/Untimely
D_GX	2/17/2008			Schedule 5A and 5B Illustration of Change in Currently Expected Royalties - Low Case and Base Case	Hearsay/Untimely
D_GY				Schedule 6A Calculation of 1/3 of Unspent Aggregate Carryover Amount and Schedule 6B Abbott's Reported Program Spending by Compound	Hearsay/Untimely
D_GZ	2/17/2008			Schedule 7A Abbott Reported Spending in 2001, Schedule 7B 2002 Annual Research Plan, Schedule 7C Calculation of Expected/Nominal Ratio and Schedule 7D "Risk Adjusted" 2002 Preliminary Annual Research Plan	Hearsay/Untimely
D_HA	3/23/2007		Davis_0001	Rule 30b6 Notice of Deposition of the Person or Persons Most Knowledgeable to Testify on Behalf of John Hancock Life Insurance Co John Hancock Variable Life Insurance Co and Manulife Insurance Co fka Investors Partners Insurance Co in Re John Hancock Life Insurance Co et al vs Abbott Laboratories (Davis 1)	Irrelevant
D_HB	3/23/2007		Davis_0002	John Hancock's Objections and Responses to Abbott Laboratories First Set of Interrogatories in Re John Hancock Life Insurance Co et al vs Abbott Laboratories (Davis 2)	No Objection
D_HC	9/21/2000	JH005573 - JH005573	Davis_0003	Bond Investment Committee Meeting Minutes (Davis 3)	No Objection
D_HD	9/21/2000	JH001203 - JH001220	Davis-0004	Purchase Recommendation For Abbott Laboratories (Davis 4)	No Objection (PL's LF)
D_HE	6/28/2001	JH0021462 - JH0021462	Davis_0005; Daesen_0001	GBSA Spreads to On the Run Treasuries (Davis 5)	No Objection
D_HF	5/8/2000	JH002423 - JH002429	Davis_0006	Blewitt Memo re: Proposed John Hancock Abbott Laboratories Transaction (Davis 6)	No Objection (PL's QQ)
D_HG	9/21/2000	JH002414 - JH002414	Davis_0007	Hartz Email re: Abbott (Davis 7)	Hearsay
D_HH	10/10/2000	JH005551 - JH005553	Davis_0008	Committee of Finance Records (Davis 8)	No Objection (PL's LG)
D_HI	3/13/2001	JH008076 - JH001105	Davis_0009	Research Funding Agreement by and between Abbott Laboratories and John Hancock Life Insurance Co et al.	Mutiple Documents
D_HJ	00/00/0000	JH001103 - JH001104	Davis_0010	Memo re: Commitment to Fund Research and Development Expenses for Abbott Laboratories	No Objection (PL's PM)

John Hancock Life Insurance Company et al. v Abbott Laboratories
Civil Action No. 05-11150-DPW

Abbott Laboratories' List of Objected To Trial Exhibits

D_D	00/00/2001	JH001446 - JH001459		DiMasi Article titled "Success Rates for New Drugs Entering Clinical Testing in the US"	Hearsay
D_HK	6/16/2004	ABBT0000077 - ABBT0000078	Martinez_0001	Desideri Letter re: Research Funding Agreement (Martinez_0001)	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_HL	4/12/2004	JHII011883 - JHII011886	Martinez_0002	Blewitt Letter re: Research Funding Agreement (Martinez 2)	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_HM	7/19/2004	ABBT0000265 - ABBT0000266	Martinez_0003	Campbell Email re: Hancock Audit (Martinez 3)	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_HN	8/31/2004	ABBT0000257 - ABBT0000260	Martinez_0005	Campbell Email re: John Hancock Audit (Martinez 5)	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_HO	10/26/2004	ABBT0000250 - ABBT0000253	Martinez_0006	Campbell Email re: Status on Documents Available for Review (Martinez 6)	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_HP	3/15/2005	ABBT0000280 - ABBT0000284	Martinez_0009	Campbell Email re: JH Abbott Audit Documentation (Martinez 9)	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_HQ	3/17/2005	JHII021526 - JHII021594	Martinez_0010	John Hancock Document Index Report (Martinez 10)	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_HR	3/11/2005	JHII021637 - JHII021643	Martinez_0019	Summary of Available Monthly Project Status Reports as of 03/11/2005 (Martinez 19)	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_HS	3/13/2001	JHII021607 - JHII021611	Martinez_0020	Compound Summary Matrix Metalloproteinase Inhibitor MMPI Program ABT-518 Overview Research Funding Agreement Highlights (Martinez 20)	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_HT	3/13/2001	JHII021612 - JHII021619	Martinez_0021	Compound Summary Cholinergic Channel Modulator ABT-594 Overview Research Funding Agreement Highlights (Martinez 21)	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have

John Hancock Life Insurance Company et al. v Abbott Laboratories
Civil Action No. 05-11150-DPW

Abbott Laboratories' List of Objected To Trial Exhibits

D_D	00/00/2001	JH001446 - JH001459		DiMasi Article titled "Success Rates for New Drugs Entering Clinical Testing in the US"	Hearsay
D_HU	00/00/2000	JHII021620 - JHII021626	Martinez_0022	Compound Summary Cholinergic Channel Modulator ABT-594 Report (Martinez 22)	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_HV	00/00/2003	JHII021627 - JHII021635	Martinez_0023	Compound Summary Dopamine Receptor Agonist Program ABT-724 Report (Martinez 23)	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_HW	3/25/2005	ABBT0000270 - ABBT0000271	Hair_0003	Campbell Email re: John Hancock Audit (Hair 3)	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_HX	3/22/2005	ABBT0000273 - ABBT0000276	Hair_0004	Hair Email re: JH Abbott Audit Documentation (Hair 4)	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_HY	4/12/2004	JHII011883 - JHII011886	Hair_0002	Davis Letter re: Research Funding Agreement by and between Abbott Laboratories and John Hancock Life Insurance Co et al. (Hair 2)	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_HZ	3/18/2005	ABBT0000277 - ABBT0000279	Hair_0005	Hair Email re: JH Abbott Audit Documentation (Hair 5)	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_IA	12/31/2001	JHII021496 - JHII021498	Daesen_0004	Schedule BA Project Equity Drug Investments YTD Report (Daesen 4)	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_IB	3/26/2002	JH002659 - JH002659	Daesen_0006	Mangan Email re: Abbott Labs (Daesen 6)	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_IC	6/27/2000	AL000115 - AL000119	Lee_0002	Proposed Summary of Terms Agreement (Lee 1)	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_ID	8/17/2000	AL000138 - AL000175	Lee_0003	Deemer Email re: Draft Agreement (Lee 3)	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have

John Hancock Life Insurance Company et al. v Abbott Laboratories
Civil Action No. 05-11150-DPW

Abbott Laboratories' List of Objected To Trial Exhibits

D_D	00/00/2001	JH001446 - JH001459		DiMasi Article titled "Success Rates for New Drugs Entering Clinical Testing in the US"	Hearsay
D_IE	10/4/2000	JH003270 - JH003341	Lee_0006	Email re: Abbott John Hancock Research Funding Agreement (Lee 6)	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_IF		JH008376 - JH008384	Lee_0017	Lee Facsimile re: Draft Research Funding Agreement	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_IG	6/8/2000	JH0012376 - JH0012388	Hartz_0002	Report re: Purchase Recommendation	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_IH	9/19/2000	JH003551 - JH003555	Hartz_0003	Email report re: Abbott	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_II	4/19/2000	JH003561 - JH003561	Hartz_0011	Email re: More Model	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_IJ	5/8/2000	JH002423 - JH002429	Hartz_0014	Memo re: Proposed John Hancock Abbott Laboratories Transaction	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_IK	9/21/2000	JH005573 - JH005573	Hartz_0019	Meeting Minutes re: Bond Investment Committee 09/21/2000	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_IL	3/13/2001	JH001103 - JH001104	Hartz_0025	Memo re: Abbott Laboratories Non Recourse	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_IM	3/26/2002	JH002659 - JH002659	Hartz_0026	Email re: Abbott Labs	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_IN	9/30/2002	JH003142 - JH003158	Hartz_0027	Email re: Abbott Labs	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have

John Hancock Life Insurance Company et al. v Abbott Laboratories
Civil Action No. 05-11150-DPW

Abbott Laboratories' List of Objected To Trial Exhibits

D_D	00/00/2001	JH001446 - JH001459		DiMasi Article titled "Success Rates for New Drugs Entering Clinical Testing in the US"	Hearsay
D_IO	3/27/2003	JH002407 - JH002409	Hartz_0032	Email memo re: Abbott Laboratories Research and Funding Agreement	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_IP	6/11/2003	JH003113 - JH003115	Hartz_0037	Email re: Abbott Research and Development Agreement	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_IQ	6/17/2003	JH003107 - JH003112	Hartz_0038	Email and Report re: Abbott Valuation	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_IR	12/19/2003	JH004479 - JH004480	Hartz_0039	Email re: John Hancock vs. Abbott Laboratories	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_IS	2/24/2005	JHII011221 - JHII011221	Hartz_0045	Email re: Abbott	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_IT	12/21/1999	ABBT0051889 - ABBT0051889	Thomas_0001	114 Sample Size	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_IU	3/7/2001	MCK00377 - MCK00386	Hopfield_0004	Presentation re: Building A World of Opportunities Together Development Portfolio Review Kick Off 03/07/2001	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_IV				Expert Report of Avram Tucker Report Support Binders Volume I-3	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_IW				Expert Report of Avram Tucker Exhibit Support Binders	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_IX	3/13/2001	MCK00423 - MCK00430	Hopfield_0005	Please Print and Put in Mail Folder	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have

John Hancock Life Insurance Company et al. v Abbott Laboratories
Civil Action No. 05-11150-DPW

Abbott Laboratories' List of Objected To Trial Exhibits

D_D	00/00/2001	JH001446 - JH001459		DiMasi Article titled "Success Rates for New Drugs Entering Clinical Testing in the US"	Hearsay
D_IY	07/00/0000	MCK00431 - MCK00437	Hopfield_0006	Initial Portfolio Prioritization	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_IZ	3/19/2001	MCK00348 - MCK00376	Hopfield_0007	R&D Integration Update Discussion Document 03/19/2001	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_JA	04/00/2001	MCK00276 - MCK00347	Hopfield_0008	Overview of Abbott R&D Fact Pack April 2001	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_JB	4/10/2001	ABBT323300 - ABBT323305	Hopfield_0009	Pharma Strategy Retreat on May 2-4, 2000	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_JC	5/5/2001	MCK00204 - MCK00275	Hopfield_0010	Resource Allocation Across GPRD Discussion Document 05/05/2001	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_JD	5/6/2001	MCK00408 - MCK00422	Hopfield_0011	Hopfield Email re: R&D Strategy Retreat Input	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_JE	06/00/2000	ABBT0570747 - ABBT0570770	Meyer_0003	ABT773 Ketolide Antibiotic 2000 Strategic Marketing Plan 06/00/2000	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_JF	9/13/2000	ABBT0557552 - ABBT0557557	Meyer_0004	ABT-773 Dev Plan	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_JG	11/28/2000	ABBT0558150 - ABBT0558150	Meyer_0005	Executive Summary of ABT-773 End of Phase 2 Mtg with FDA	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_JH	11/29/2000	ABBT0556816 - ABBT0556822	Meyer_0006	Slides for 12/05/2000 Meeting	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have

John Hancock Life Insurance Company et al. v Abbott Laboratories
Civil Action No. 05-11150-DPW

Abbott Laboratories' List of Objected To Trial Exhibits

D_D	00/00/2001	JH001446 - JH001459		DiMasi Article titled "Success Rates for New Drugs Entering Clinical Testing in the US"	Hearsay
D_JI	12/5/2000	ABBT0577000 - ABBT0577168	Meyer_0007	ABT-773 Portfolio Review 12/05/2000	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_JJ	02/00/2001	ABBT0000387 - ABBT0000399	Meyer_0008	February 2001 ABT-773 Tab Ketolide Antibiotic Tablet	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_JK	2/12/2001	ABBT205042 - ABBT205046	Meyer_0009	ABT-773 Update 02/12/2001	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_JL	2/22/2001	ABBT204959 - ABBT205041	Meyer_0011	773 Material	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_JM	2/14/2001	ABBT0568172 - ABBT0568172	Meyer_0012	Re: Studies to Meet Pediatric Rule Requirements	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_JN	02/00/2001	JH008153 - JH008158	Meyer_0015	ABT-773 Descriptive Memorandum February 2001	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_JO	3/9/2000	ABBT0141929 - ABBT0141983	Nabulsi_0001	Presentation re: Matrix Metalloproteinase Inhibitors Project Discovery Development Candidate Meeting 03/09/2000 A291518 for Treatment of Cancer	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_JP	08/00/2000	ABBT0092083 - ABBT0092094	Nabulsi_0003	Report re: ABT-518 Transition Strategy MMPI	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_JQ	02/00/2001	ABBT0000343 - ABBT0000348	Nabulsi_0006	Project Status Report re: February 2001 ABT-518 Matrix Metalloproteinase Inhibitor	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_JR	3/9/2001	ABBT0013224 - ABBT0013232	Nabulsi_0009	Presentation re: Abbott Portfolio review March 7-9, 2001	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have

John Hancock Life Insurance Company et al. v Abbott Laboratories
Civil Action No. 05-11150-DPW

Abbott Laboratories' List of Objected To Trial Exhibits

D_D	00/00/2001	JH001446 - JH001459		DiMasi Article titled "Success Rates for New Drugs Entering Clinical Testing in the US"	Hearsay
D_JS	3/8/2001	ABBT0045253 - ABBT0045253	Nabulsi_0010	Meeting Documents re: MMPI Monthly Meeting Agenda 03/08/2001	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_JT	3/8/2001	ABBT300143 - ABBT300144	Nabusli_0011	Meeting Documents MMPI Working Group Meeting Minutes 03/08/2001	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_JU		ABBT0507866 - ABBT0507866	Nabulsi_0012	Memo re: Project review	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_JV	12/11/2001	ABBT0518377 - ABBT0518378	Nabulsi_00013	Report re: Timeline of Events Occurring with Study M00235 in the Netherlands	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_JW	3/12/2001	ABBT0060788 - ABBT0060788	Nabulsi_00014	Email re: M00235 Update	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_JX	5/25/2001	ABBT0061200 - ABBT0061200	Nabulsi_00017	Email re: ABT-518	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_JY	4/12/2001	ABBT0045243 - ABBT0045245	Nabulsi_00021	Meeting Documents re: MMPI Monthly Meeting Agenda 04/12/2001	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_JZ	05/00/2001	ABBT143915.UR - ABBT143920.UR	Nabulsi_00024	Project Status report re: May 2001 ABT-518 Matrix Metalloproteinase Inhibitor	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_KA	00/00/2001	ABBT0059550 - ABBT0059556	Nabulsi_00026	Presentation re: ASCO 2001 MMPI Update	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_KB	1/15/1999	ABBT0005027 - ABBT0005030	Meyer_00001	01/15/1999 Meeting Minutes Analgesia Venture Portfolio Review	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have

John Hancock Life Insurance Company et al. v Abbott Laboratories
Civil Action No. 05-11150-DPW

Abbott Laboratories' List of Objected To Trial Exhibits

D_D	00/00/2001	JH001446 - JH001459		DiMasi Article titled "Success Rates for New Drugs Entering Clinical Testing in the US"	Hearsay
D_KC	04/00/1999	ABBT0020594 - ABBT0020611	Meyer_00003	ABT-259 Transition Strategy	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_KD	2/2/2001	ABBT314925 - ABBT314926	Meyer_00012	DSG	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_KF	2/19/2001	ABBT0115991 - ABBT0115993	Meyer_00013	Scientific Strategy for ABT-594 NNR Tolerability	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_KG	03/00/2001	ABBT0024132 - ABBT0024153	Meyer_00016	Global Pharmaceutical Discovery Internal Review 03/00/2001 Book Number 27	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_KH	3/8/2001	ABBT298379 - ABBT298379	Meyer_00018	ABT-594 Pain Strategy DSG 03/05/00 Meeting Minutes	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_KI	3/12/2001	ABBT0022006 - ABBT0022008	Meyer_00019	Calendar Entry	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_KJ	4/23/2001	ABBT0001749 - ABBT0001758	Meyer_00020	M99114 Study Review	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_KK	6/7/2002	ABBT0108742 - ABBT0108779	Meyer_00026	DDC Slides	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_KL	6/13/2002	ABBT0023982 - ABBT0024053	Meyer_00027	DDC A429202 Neuronal Nicotinic Receptor NN Agonist	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_KM			Meyer_00029	Neuroscience and Pain	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have

John Hancock Life Insurance Company et al. v Abbott Laboratories
Civil Action No. 05-11150-DPW

Abbott Laboratories' List of Objected To Trial Exhibits

D_D	00/00/2001	JH001446 - JH001459		DiMasi Article titled "Success Rates for New Drugs Entering Clinical Testing in the US"	Hearsay
D_KN	9/13/2000	ABBT0557552 - ABBT0557557	Fox_00002	Email re: ABT-773 Dev Plan	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_KO	11/20/2000	ABBT0558681 - ABBT0558683	Fox_00003	Email report re: FDA Telephone Contract report ABT-773	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_KP	2/12/2001	ABBT205042 - ABBT205046	Fox_00008	report re: ABT-773 Update 02/12/2001	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_KQ	2/14/2001	ABBT0568172 - ABBT0568172	Fox_00010	Email re: Studies to Meet Pediatric Rule requirements	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_KR	3/13/2001	JH008076 - JH008211	Leiden_0001	Letter Agreement re: Research Funding Agreement Dated as of 03/13/2001	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_KS	3/9/2001	ABBT0092919 - ABBT0092921	Leiden_0005	Meeting Documents re: Portfolio Review Meeting 03/07/2001 to 03/09/2001 the Hyatt Deerfield	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_KT	07/00/0000	ABBT0155602 - ABBT0155608	Leiden_0007	Report re: Initial Portfolio Prioritization	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_KU	09/00/2000	ABBT0155493 - ABBT0155512	Leiden_0010	Presentation re: Pharmaceuticals Strategy Update 09/00/2000	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_KV	09/00/2000	ABBT0577835 - ABBT0577854	Leiden_0011	Presentation re Pharmaceuticals Strategy Update 09/00/2000	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_KW	10/12/2000	ABBT0118072 - ABBT0118072	Leiden_0014	Email re: NNR Documents	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have

John Hancock Life Insurance Company et al. v Abbott Laboratories
Civil Action No. 05-11150-DPW

Abbott Laboratories' List of Objected To Trial Exhibits

D_D	00/00/2001	JH001446 - JH001459		DiMasi Article titled "Success Rates for New Drugs Entering Clinical Testing in the US"	Hearsay
D_KX	12/00/2000	ABBT0004460 - ABBT0004464	Leiden_0020	Project Status Report re: 12/00/2000 ABT-594 Project Status Report	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_KY	3/2/2001	ABBT0037509 - ABBT0037608	Leiden_0022	Memo Report re 00/00/2001 Plan Final Reference Package	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_KZ	12/11/2001	ABBT0518377 - ABBT0518378	Leiden_0030	Report re: Timeline of Events Occurring with Study M00235 in the Netherlands	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have
D_LA	10/9/2001	ABBT0148334 - ABBT0148334	Leiden_0033	Email re: ABT-594 Not Funded	Added to exhibit list on February 18, 2008; Abbott has provisionally assigned these exhibits letter designations to preserve any objections Hancock may have

John Hancock v. Abbott Laboratories**John Hancock's Objections to Abbott's Revised List of Proposed Trial Exhibits**

Key	
Code	Objection
AUTH	The proposed exhibit does not sufficiently indicate that it is what it purports to be, and is inadmissible under Fed. R. Evid. 901.
BATES	The proposed exhibit denotes a Bates range that appears to be in error. John Hancock requests that Abbott properly identify the proposed exhibit. Further, John Hancock reserves all objections to these documents.
HEAR	The proposed exhibit is Hearsay or Double Hearsay not within any exception, and is inadmissible under Fed. R. Evid. 802
IRREL	The proposed exhibit is irrelevant under Fed. R. Evid. 401, and thus inadmissible under Fed. R. Evid. 402.
MULTI	The proposed exhibit identifies more than one document. John Hancock requests that Abbott identify these documents with separate exhibit numbers. John Hancock reserves all objections to such documents.
No Objection	John Hancock does not object to the proposed exhibit.
SETTL	The proposed exhibit deals with settlement discussions and is thus inadmissible under Fed. R. Evid. 408.
PLs' "xx"	Abbott's proposed trial exhibit has been proposed as a trial exhibit by John Hancock, and has been objected to by Abbott. John Hancock urges Abbott to withdraw its objection to documents that Abbott now offers as trial exhibits in its own case.
Ex. "xx"	Abbott's proposed trial exhibit has been proposed as a trial exhibit by John Hancock, and has not been objected to by Abbott. The exhibit exists on the parties' list of "Agreed To" exhibits.
UNTIMELY	The proposed exhibit is being submitted by Abbott as part of the expert report of Avram Tucker. The exhibit was not previously included in that expert report, as required under the Scheduling Order in this case, and under Fed. R. Civ. P. 26(a)(2)(B). Hancock therefore objects to the exhibit as untimely.